Registration of clinical trials is the focus of #MakeitPublic week 2024, taking place from Monday 18 March this year.

Promoting research transparency is a key part of our work to facilitate safe and ethical research. When research is carried out openly and transparently, everyone benefits.

This year, for the first time, we are publishing on our website a full list of clinical trials that received a favourable opinion from a Research Ethics Committee (REC) in 2022, with the registration details that we hold for them. There is an expectation that following a favourable opinion from a REC, the clinical trial sponsor will register this on a World Health Organisation (WHO) compliant registry and update the HRA with these details. Read more about the work RECs do.

Information about these trials is already available in our research summaries database, but this list provides a quick reference to all those which received a REC favourable opinion in 2022 with their registration numbers. There are a total of 1545 trials.

Over the last few months we've asked research sponsors and chief investigators, who are responsible for registering clinical trials, for their trial’s registration number if we didn’t already have this information. It is a condition of favourable opinion of a REC that clinical trials are registered in a public registry before the first participant is recruited and no later than six weeks after.

If we did not receive a reply, we searched online to see if the trial was registered on a public registry. If we found a registration number by searching, we’ve put this in the tables below.

Being transparent with the data we hold about clinical trials - even if this is sometimes incomplete - helps us to build trust in research. We will continue to work with trial sponsors and others involved in health and social care research to improve the information we hold and share.

Read a blog from our Deputy Director of Policy and Partnerships, Naho Yamazaki, on the importance of research transparency and what we’re doing to improve our own systems and processes.

What we are publishing

We have published data about clinical trial registration every year since 2015. This has usually been a snapshot audit to show the proportion of trials that are registered. We have not published registration information on a trial-by-trial basis before.

This year we are sharing data on clinical trials in the UK that received a favourable opinion from RECs in 2022, with details on their registration number or an explanation for non-registration when this has been shared with us. Where there is no information displayed, it is because we do not hold registration details or an explanation for non-registration.

The tables you see below contain data we held in March 2024. Updates after this date will be used in future lists. This one remains a snapshot of the position this week.

Thank you to everyone who has been involved in collecting, collating, checking, and responding to this request for data.

Why we are publishing this data now

By publishing this information we can work towards improving research transparency more widely, and support our vision of making information from health and social care research studies publicly available for the benefit of all.

If you are a sponsor for a clinical trial, and you didn’t receive an email asking for your data, this might be because we don’t have the correct contact details for you.

Please note it is a requirement for you to keep us up to date with any changes to your contact details. Please take a moment to check that we hold the correct details for you, and please also contact us with any further updates on your clinical trial.

Making it easier to be transparent about your research

We are holding a workshop on Thursday 21 March, which will highlight best practice in research transparency and discuss how to make registration as easy as possible for people running a clinical trial. Find out more on the Make it Public week 2024 page.

We want to hear from you about any barriers you experience in registering a trial, to better understand how we can improve our systems and processes. This will also be an opportunity to find out more about the transparency requirements, and how you can meet them.

This event is now fully booked, but we’ll share more information afterward including a summary of the feedback and discussions from the day.

Our handy map follows your study from idea to publication with guidance on research transparency every step of the way.

What we found

Graph showing the percentage of clinical trials in 2022 that were registered. It shows that 92% were registered and 8% were unregistered.

More than nine out of 10 clinical trials met their registration requirements, an increase on previous years.

Graph showing where clinical trials are registered. 32% are registered on the ISRCTN. 66% are registered on ClinicalTrials.gov and 55% are on another registery recognised by the World Health Organisation (WHO).

Two thirds of clinical trials were registered on ClinicalTrials.gov. The total is over 100% as some studies are included on more than one registry.

Graph showing the source of registration details. It shows that 89% of studies were registered and the sponsor informed the HRA. For 3% of studies that were registered, the sponsor did not inform the HRA. 3% of studies were not registered, but the sponsor has told us why not. 5% of studies were not registered and the sponsor has not told us why

For almost all of the registered clinical trials, the sponsor informed us it was registered.

Graph showing the explanations for non-registration of clinical trials. 6% are currently registering. 1% forgot to register. 1% were not aware of the requirement. 11% no longer considered their study a clinical trial. For 1% recruitment had not yet started. For 1% the trial did not open in the UK. 2% were withdrawn before any participants were recruited. 77% did not respond.

The most common explanation for non-registration was because the sponsor no longer considered the study a clinical trial. Over three quarters of those we contacted regarding the registration status of their trials did not respond.

Registration data

We have arranged the studies in the tables below by the month in which they given favourable opinion by a Research Ethics Committee (REC). The tables are long, you can jump to a specific month by using the menu. Within each month the studies are arranged by IRAS number, in order. This is a number given to a study when the first application for approvals is made and which follows the study through its lifecycle, until the results are published.

The full data set is also available as a CSV file.

There is not one single registry for clinical trials. The format of the number in the table below can tell you which register the study has used.

ISRCTN - Numbers beginning ISRCTN

Clinicaltrials.gov - Numbers beginning NCT

EudraCT - Numbers in three parts beginning with a year, for example 2019-xxxxx-xx

ANZCTR - Numbers beginning ACTRN

DRK - Numbers beginning DRK


If there is no data in the registration number column, we do not have a record of the study being registered. If the study's sponsor responded to us with information about why their study is not registered, we have included their explanation in the final column. Where we have noted 'found through search', we mean the study's registration details were found when we looked for them online using a search engine.

Clinical trials given a REC favourable opinion in January 2022

IRAS ID Full study title Sponsor organisation Registration number Further information
256101 Tolerance, compliance and acceptability to a new nutritional feed comprising real food ingredients Nutricia NCT05269992
261868 Phase I/II, non-randomised, open-label study of pCCLChimp47 (Lentiviral vector transduced CD34+ cells) in patients with p47 Autosomal Recessive Chronic Granulomatous Disease (AR-CGD) Great Ormond Street Hospital for Children NHS Trust NCT05207657; 2019-001210-42
262719 Calcium Supplementation for Prevention of Pre-eclampsia in High Risk Women: CaPE Trial University of Birmingham ISRCTN12033893; 2020-004435-25
277601 Clinical and patient reported outcomes following treatment of grade III furcation involved molars. A single-centre single-masked randomised controlled feasibility trial with a Sequential, Multiple Assignment Randomised Trial (SMART) design King’s College London NCT05237739 Found through search but HRA not notified
278200 To evaluate a parent-led, individualised sleep promotion package in children and young people having medium or long stay on the cardiac Paediatric Intensive Care Unit (PICU) Newcastle Upon Tyne Hospitals NHS Foundation Trust Sponsor no longer considers this a clinical trial
280020 Complex intervention comprising text MEssaging anD HEalthcare professionaL training for imProving statin adherence in primary care: a pragmatic cluster-randomised controlled trial (MED-HELP) University of Leicester ISRCTN13245243
283413 International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones University of Milano-Bicocca NCT03007147; 2017-000705-20
284870 Randomised Open-label Phase II study of induction standard of care Fulvestrant and CDK4/6 inhibition with the Addition of Ipatasertib in Metastatic ER+/HER2- breast cancer patients without ctDNA suppression The Royal Marsden NHS Foundation Trust NCT04920708; 2020-002825-27
286685 Efficacy of doravirine + dolutegravir dual therapy in the context of antiretroviral therapy switch Chelsea and Westminster Hospital NHS Foundation Trust NCT04892654; 2020-003928-17
286785 RATinG (Risk Adapted Therapy in acute GvHD): Investigating the use of lenzilumab for treating high-risk acute graft versus host disease following allogeneic stem cell transplantation University of Birmingham ISRCTN42585840; 2021-001193-29
287123 Near Infrared Fluorescence (NIRF) Imaging to prevent Post-surgical Hypoparathyroidism (PoSH)after Thyroid Surgery (NIFTy) - A phase II/III pragmatic, multicentre randomised controlled trial Sheffield Teaching Hospitals NHS Foundation Trust ISRCTN59074092
287151 NanaBis™ An Oro–Buccal Administered Equimolar THC and CBD Formulation as Monotherapy for the Management of Opioid-Requiring Chronic Pain – Due to Metastatic Bone Cancer: A Phase 3 Multi-Centre, Double-Blind, Randomised-Withdrawal Active and Placebo-Controlled Clinical Study Medlab Clinical 2021-001540-98
289862 A multi-centre, controlled study to evaluate the efficacy and safety of an Endoscopic Sutured Gastroplasty (with Endonima device) in patients with non-alcoholic steatohepatitis (NASH) and fibrosis Erasme University Hospital NCT04653311
290490 Feasibility of a breakfast group intervention for acute stroke units, to provide intensive eating and drinking interventions as well as integrated multi-disciplinary team working and personalised care Sheffield Teaching Hospitals NHS Foundation Trust NCT05102812 Found through search but HRA not notified
290871 First-in-Human Trial of the Safety and Performance of NU-MAX® (IEIK13) as a Hemostatic Agent in Intracranial Neurosurgery 3-D Matrix NCT04953949
291027 RCT of group CBT for men with intellectual and/or developmental disabilities and harmful sexual behaviour: the HaSB-IDD trial University of Kent ISRCTN21187053
291170 Biomarkers and Rapid Imaging in Dementia Diagnosis: B-RAPIDD University College London ISRCTN12777415
292742 Open-Label Extension Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Patients With Homozygous and Heterozygous Familial Hypercholesterolemia, Cardiovascular Disease, or at High Risk for Cardiovascular Disease, on Stable Lipid-Lowering Therapy Requiring Additional Low-Density Lipoprotein Cholesterol Reduction (LIBerate-OLE) LIB Therapeutics NCT04798430; 2020-004394-49
293304 Volume targeted versus pressure targeted non-invasive ventilation in amyotrophic lateral sclerosis: a randomised control trial University Hospitals Coventry & Warwickshire NHS Trust NCT05328492 Found through search but HRA not notified
293430 A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia (CONNEX-3) Boehringer Ingelheim NCT04860830; 2020-003726-23
294469 DIALOG+ in Primary Care: A Proof of Concept Study Queen Mary University of London ISRCTN46897021
294830 Pilot of EMG-Directed Virtual-Reality Experience Training for Motor Stroke Rehabilitation Imperial College London NCT05253989
295260 Optical Coherence Tomography Angiography for the detection of Neovascular Age-related Macular Degeneration: a Comprehensive Diagnostic Accuracy Study Moorfields Eye Hospital NHS Foundation Trust ISRCTN18313457
296162 Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications Including Bronchial and Thymic Neuroendocrine Tumour, Paraganglioma/ Phaeochromocytoma, Medullary Thyroid Carcinoma, and Those Requiring Repeat Peptide Receptor Radionuclide Therapy (Phase 2 trial) University College London 2021-002925-12
296622 Endometriosis Fertility Index: A Non-Surgical Approach Guy's & St Thomas' NHS Foundation Trust
297060 Reirradiation Options for Previously Irradiated Prostate cancer (RO-PIP): Feasibility randomised clinical trial investigating toxicity outcomes following reirradiation with ultra-hypofractionated external beam radiotherapy vs. high dose rate brachytherapy University of Leeds ISRCTN12238218
298246 Effectiveness of the EMPOWER™ Modular Pacing System and EMBLEM™ Subcutaneous ICD to Communicate Antitachycardia Pacing Boston Scientific NCT04798768
298683 Mechanisms & Innovations in Right Ventricular Pacing for Hypertrophic Obstructive Cardiomyopathy (HOCM) Imperial College London and Imperial College Healthcare NHS Trust NCT05257772
298740 A Phase 2 Open-Label Clinical Trial of ADP-A2M4CD8 in Subjects with Advanced Esophageal or Esophagogastric Junction Cancers Adaptimmune NCT04044859; 2020-005802-24
298952 Respiratory Infections - Rapid Test Evaluation: a platform study for clinical validation of novel rapid devices in respiratory infection Imperial College London
300145 HEmodynamic effects of Reducing lv Afterload with impella or intra-aortic balloon CounterpuLsation during veno-arterial Extracorporeal membrane oxygenation in cardiogenic Shock King’s College London ISRCTN82431978
300383 129Xe Mri Assessment Of Disease Progression In Patients With Chronic Obstructive Pulmonary Disease Treated With Standard-Of-Care Medications With Or Without Daily Open-Label Azithromycin Treatment To Prevent Acute Exacerbation Genentech 2020-000852-36
300828 Salaso Moving More: The impact of digitally delivered precision exercise in helping people to move more Bangor University NCT05918926
300829 A Phase 3 Multicenter, Open-Label, Randomized Study of Navicixizumab Plus Paclitaxel and Navicixizumab Monotherapy in Comparison to Paclitaxel Monotherapy in Patients with Platinum-Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer OncXerna Therapeutics NCT05043402; 2021-001933-38
300914 Advance Statements for Black African and Black Caribbean people (AdStAC) King’s College London Sponsor no longer considers this a clinical trial
301026 A single case experimental design study of a reminder app for supporting adherence to personalised treatment goals in Parkinson’s Disease NHS Greater Glasgow & Clyde NCT05106985
301126 Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation after Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT Mercator MedSystems NCT04862468; 2021-002798-24
301477 A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Apellis NCT05067127; 2020-003767-25
301526 A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children, Adolescents, and Young Adults with Fragile X Syndrome - RECONNECT Zynerba NCT04977986; 2021-002542-33
301776 RESPOND study (Rescue for Emergency Surgery Patients Observed to uNdergo acute Deterioration) Work Package 3: Feasibility Trial University of Oxford NCT04919720
302010 Development Study to Undertake a Comprehensive Performance Evaluation of Prototype Non-Invasive Blood Glucose Measurement Systems Compared to a Standard (Invasive) Measurement Method of Blood Glucose Afon Technology NCT05023798
302061 Sham controlled Randomized Control Trial evaluating the Safety, Acceptability and Efficacy of Autonomic neuromodulation using trans-cutaneous vagal sensory stimulation in uncontrolled hypertensive patients: a pilot study evaluating a novel non-invasive device-based strategy Barts Health NHS Trust & Queen Mary University of London ISRCTN14509154; NCT05179343
302069 Proactive review for people with diabetes in hospital: a cluster randomised feasibility study and process evaluation Cambridge University Hospitals NHS Foundation Trust ISRCTN70402110
302079 A Phase 1b, Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Multiple Doses of ELA026 in Adults and Adolescents with Secondary Hemophagocytic Lymphohistiocytosis (sHLH) Electra Therapeutics 2021-001387-20
302216 Emergency Medical Services Streaming Enabled Evaluation In Trauma University of Surrey ISRCTN11449333
302239 A Phase Ia study to assess safety and immunogenicity of the Plasmodium vivax malaria vaccine candidate Pvs25-IMX313 in Matrix-M1 adjuvant in healthy adults living in the UK University of Oxford NCT05270265; 2021-003550-23
302310 Investigating effects of mindfulness training on DMN connectivity and dynamics University of Surrey NCT05650177
302371 The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects with Primary Biliary Cholangitis (PBC) and Hepatic Impairment CymaBay Therapeutics NCT04950764; 2020-005925-10
302393 Efficacy, tolerability and acceptability of the single tablet regimen (STR) Biktarvy® by trans people living with HIV (TPLWH) Chelsea and Westminster Hospital NHS Foundation Trust NCT04944654; 2020-001070-29
302533 An open-label trial of the long-term safety and tolerability of nintedanib per os, on top of standard of care, over at least 2 years, in children and adolescents with clinically significant fibrosing Interstitial Lung Disease (InPedILD™-ON) Boehringer Ingelheim NCT05285982; 2020-005554-23
302606 A Phase II, Double-blind, Placebo-controlled, Randomized, Dose-ranging, Parallel Group Study to Evaluate the Safety and Efficacy of PHA-022121 Administered Orally for Prophylaxis Against Angioedema Attacks in Patients with Hereditary Angioedema due to C1-Inhibitor Deficiency (Type I or Type II) Pharvaris NCT05047185; 2021-000227-13
302650 A multicenter, Phase 3, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the saftey and efficacy of PTX-022 in the treatment of moderate to severe Pachyonychia Congenita Palvella Therapeutics NCT05180708 ; 2021-003136-10
302709 PARABLE: Proton beam therapy in patients with breast cancer: evaluating early and late effects Institute of Cancer Research ISRCTN14220944
302827 ShorT stay Aneurysm Repair (STAR): A 23-hour endovascular abdominal aortic aneurysm repair pathway with evaluation of eligibility, uptake, viability, acceptability, safety and cost Imperial College London NCT05279274
302833 The role of an implantable Doppler vascular monitoring device in kidney transplant patients: a feasibility randomised controlled trial with an embedded qualitative study University Hospital Plymouth NHS Trust NCT05634863
302967 Utilising an innovative MCM5 Urine TEst foR the dIagnosis of eNdometrial cancEr (MCM5-UTERINE study) Arquer Diagnostics NCT05287048
303172 Utility of Novel Echocardiographic and Invasive Haemodynamic Measurements in the assessment of patients with Low Flow Low Gradient Aortic Stenosis undergoing TAVI; A pilot study. The Royal Wolverhampton NHS Trust NCT05196815
303213 Myopia Control Contact Lenses Non-Dispensing Phase Generic Application for a Family of Prototypes CooperVision
303831 Personalised Primary care for Patients with Multimorbidity (PP4M) – a primary care service improvement initiative University of Bristol ISRCTN40295449
303839 A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure Janssen-Cilag International NCT04988295; 2021-001825-33
303876 STOP- Successful Treatment Of Paranoia: Replacing harmful paranoid thoughts with better alternatives King’s College London ISRCTN17754650
304233 Influence of vitamin D and a probiotic on inflammation and gut bacteria University of Southampton ISRCTN10131460
304242 An Open-Label, Multicenter, Outpatient Extension Study to Evaluate the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older with Stereotypical Prolonged Seizures UCB NCT05076617; 2021-002637-42
304379 A Phase 1, Open-Label, Parallel-Group Study to Evaluate the Safety, Immunogenicity, and Reactogenicity of Heterologous and Homologous Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in B-Cell Deficient Patients Gritstone bio 2021-004179-14
304419 Early identification of Pre-diabetes and evaluation of Lifestyle Therapy in Children and Adolescents with Obesity using Continuous Glucose Monitoring System Alder Hey Children's Hospital
304706 Corcym Mitral, Aortic aNd Tricuspid post-maRket Study in a reAl-world setting Corcym NCT05002543
304770 An open label, multi-centre study to evaluate the long-term safety and tolerability of REN001 in subjects with primary mitochondrial myopathy (PMM) Reneo Pharma NCT05267574; 2021-003471-34
304976 The Evaluation and Performance of the Raspberry Pi Bone conduction hearing device for adults with hearing loss at an ENT/Audiology outpatient clinic Liverpool School of Tropical Medicine
305153 To establish whether the Occuity device is non inferior in its measurement of central corneal thickness compared to Accutome ultrasound pachymeter and Lenstar Portsmouth Hospitals University NHS Trust
305546 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of Orismilast in Adults with Moderate-to-Severe Plaque-Type Psoriasis UNION Therapeutics NCT05190419; 2021-003209-22
305684 A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of QR-421a in Subjects with Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene with Early to Moderate Vision Loss ProQR Therapeutics NCT05176717; 2021-002728-19
305709 Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, with Cross-Over, of Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation AlloVir NCT05179057; 2021-003450-22
305777 A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator’s Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects with KRAS p.G12C Mutation Amgen NCT05198934; 2021-004008-16
305781 Adult-caregiver Supported Positive psychology intervention to Increase Resilience (ASPIRE): developing and refining a caregiver-delivered positive psychology intervention to increase the resilience of children who have experienced adversities (Work Package 2) Norfolk and Suffolk NHS Foundation Trust
305798 A Wearable Device for Cueing for the management of drooling, and monitoring of symptoms, in people with Parkinson’s Northumbria Healthcare NHS Foundation Trust ISRCTN59284050
305919 A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects with Idiopathic Pulmonary Fibrosis CSL Behring NCT05130970; 2021-003162-12
306258 BEhaviour change to reduce Pain in Knee Osteoarthritis (BEPKO-2) - Feasibility study University of Salford ISRCTN25291958
306483 Avelumab Master Protocol: An Open-Label Continuation Study For Participants Continuing From Pfizer Sponsored Avelumab Clinical Studies Pfizer NCT05059522; 2021-002457-29
306756 Cognitive Stimulation Therapy for people with Intellectual Disabilities and Dementia (CST-IDD). A mixed methods feasibility study North East London NHS Foundation Trust ISRCTN88614460
306797 The effect of low-dose interleukin-2 on the immune landscape of human atherosclerotic plaques at single cell resolution Cambridge University Hospitals NHS Foundation Trust & University of Cambridge NCT05975554
306840 The effect of inorganic nitrate supplementation on brown fat activation and quantity in people with type 2 diabetes mellitus Bournemouth University NCT05342012
306901 An open-label, multicenter Phase I dose escalation study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics and maximum tolerated dose of VIP152(BAY 1251152) in subjects with advanced cancer Vincerx Pharma NCT02635672; 2014-004808-30
306930 Comprehensive Assessment of Nutrition & Dietary Intervention in Hypermobile Ehlers Danlos Syndrome (hEDS/HSD): a personalised approach: Phase 2 & 3 Queen Mary University of London NCT05148039
306939 A pilot study of the ketogenic diet in bipolar disorder University of Edinburgh ISRCTN61613198
306940 An Open-label, Fixed Sequence Study in Healthy Subjects to Assess the Pharmacokinetics of AZD4831 when Administered Alone and in Combination with Rifampicin AstraZeneca 2021-005695-19
306941 An Open-label, Fixed Sequence Study in Healthy Subjects to Assess the Pharmacokinetics of AZD4831 when Administered Alone and in Combination with Itraconazole AstraZeneca 2021-005727-21
307070 A randomised, double-blind, placebo controlled, parallel group study in healthy adult volunteers to determine the safety and tolerability of pyronaridine (PYR) co-administered with piperaquine (PQP) under fasted conditions Medicines for Malaria Venture NCT05160363; 2021-005698-21
307348 Does domiciliary Nasal High Flow (NHF) therapy improve patient outcomes in Chronic Hypercapnic Respiratory Failure (CHRF) in the UK?: A pre and post interventional study Royal Free London NHS Foundation Trust NCT05167201
307830 Building positive self-concept in patients with psychosis: a single-case experimental design series testing a targeted psychological treatment University of Oxford
308063 A Phase I, Single-site, Open-label, Partially Randomized Study to Evaluate the Relative Bioavailability and Pharmacokinetics of Evobrutinib Following Administration of Different Formulations in Healthy Participants Merck KGaA NCT05245396; 2021-005056-11
308193 A Phase I, open-label, fixed-sequence, two-period, crossover, drug-drug interaction study to evaluate the effect of multiple doses of ganaplacide and lumefantrine combination on the pharmacokinetics of midazolam, repaglinide, dextromethorphan, metformin, rosuvastatin and dolutegravir in healthy participants Novartis NCT05236530; 2021-000926-87
308539 “AveirTM DR i2i Study” Aveir Dual-Chamber Leadless i2i IDE Study Abbott NCT05252702
310206 A proof of principle (PoP) study to evaluate the ability of an experimental combination toothpaste formulation to protect sensitive teeth from dentine hypersensitivity GlaxoSmithKline NCT05243745 Found through search but HRA not notified
310749 A multicentre Cluster Randomised pilot study comparing current Endoscopic (keyhole) vein harvesting training with Structured Training -  The CREST trial Manchester University NHS Foundation Trust ISRCTN27493194
310753 A Fixed-Sequence, Drug-Drug Interaction Study Evaluating the Effect of the Cytochrome P450 3A Inhibitor Itraconazole on DNL343 in Healthy Participants Denali 2021-006382-37
311335 Evaluation of the diagnostic performance of the Rapid SARS-CoV-2 Antigen Test Card for Covid-19 Sante Group ISRCTN12682933
1003784 A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects with Selected Proteinuric Glomerular Diseases (EPPIK) Travere Therapeutics NCT05003986; 2021-000621-27
1003876 A proof-of-concept randomised intervention trial to establish the impact of prasugrel versus aspirin on the proinflammatory and prothrombotic effects of experimental hypoglycaemia in type 2 diabetes Sheffield Teaching Hospitals NHS Foundation Trust ISRCTN53525957; 2021-002906-28
1003970 A stratified randomised controlled trial to evaluate the clinical and cost-effectiveness of Stimulant compared with Non-stimulant medication for adults with Attention-deficit/hyperactivity disorder and a history of Psychosis or biPolar disordER University of Birmingham ISRCTN79796233; 2021-000302-21
1003972 FEDORA: A phase II study to evaluate the tolerability, safety and activity of fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis University of Birmingham ISRCTN88102629; 2021-004056-42
1003976 A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis Horizon Therapeutics NCT04781543; 2020-005764-62
1003994 A prospective, open-label, genotype-match controlled, multicenter clinical trial to investigate the efficacy and safety of intra-amniotic ER004 as a prenatal treatment for male subjects with X-linked hypohidrotic ectodermal dysplasia (XLHED) EspeRare Foundation NCT04980638; 2021-002532-23
1004044 A Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the DNA Polymerase Theta Inhibitor ART4215 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumours Artios NCT04991480; 2021-002574-69
1004059 A Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of BMS-986256 in Participants with Active Systemic Lupus Erythematosus Bristol-Myers Squibb NCT04895696; 2019-004021-25
1004066 Pembrolizumab in combination with R-ICE chemotherapy in relapsed/refractory diffuse large B-cell lymphoma University Hospital Southampton NHS Foundation Trust ISRCTN86607306; NCT05221645; 2018-001886-18
1004073 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension (PAH) World Health Organization (WHO) Functional Class (FC) III or FC IV at High Risk of Mortality Acceleron Pharma NCT04896008; 2021-001498-21
1004084 A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Bendamustine plus Rituximab in Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-313) Loxo Oncology NCT05023980; 2021-001234-20
1004109 A Pivotal Trial Of Envafolimab, And Envafolimab In Combination With Ipilimumab, In Patients With Advanced Or Metastatic Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma Who Have Progressed On Prior Chemotherapy TRACON Pharma NCT04480502; 2021-004319-22
1004175 A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of an age-and body weight-adjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children, 6 months to <18 years of age, with chronic kidney disease and proteinuria Bayer NCT05196035; 2021-002071-19
1004197 Phase 2, Double-blind, Randomized, Placebocontrolled Study to Evaluate the Effects of Sotatercept versus Placebo-Controlled for the Treatment of Combined  Postcapillary and Precapillary Pulmonary Hypertension  (Cpc-PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF) Acceleron Pharma NCT04945460; 2021-003020-32
1004198 Open-label study investigating efficacy, safety and pharmacokinetics of concizumab prophylaxis in children below 12 years with haemophilia A or B with or without inhibitors Novo Nordisk NCT05135559; 2020-000504-11
1004213 A Modular Phase II, Open-label, Multicentre Study to Assess AZD4573 Efficacy and Safety as Monotherapy or in Combination with Anti-cancer Agents in Patients with Relapsed/Refractory Peripheral T-cell Lymphoma or classical Hodgkin Lymphoma AstraZeneca NCT05140382; 2021-002570-54
1004224 Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to Assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation positive Stage IA2-IA3 Non-small Cell Lung Cancer, following Complete Tumour Resection AstraZeneca NCT05120349; 2021-004135-89
1004228 A Two-Part, Seamless, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics And Efficacy Of Ro7204239 In Combination With Risdiplam (Ro7034067) In Ambulant Patients With Spinal Muscular Atrophy Roche NCT05115110; 2021-003417-19
1004246 A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Safety, Efficacy, And Pharmacodynamics Of 52 Weeks Of Treatment With Basmisanil In Children With Dup15Q Syndrome Roche NCT05307679; 2021-003791-13
1004247 A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication Alnylam NCT05103332; 2021-003776-13
1004257 A Phase III, Randomized, Open-Label, Multicenter Study Of Lurbinectedin In Combination With Atezolizumab Compared With Atezolizumab As Maintenance Therapy In Participants With Extensive-Stage Small-Cell Lung Cancer (Es-Sclc) Following First-Line Induction Therapy With Carboplatin, Etoposide And Atezolizumab Roche NCT05091567; 2021-001930-20
1004258 A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI3506 in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (TITANIA) AstraZeneca NCT05158387; 2021-003771-34
1004290 The FINESSE Study: A randomised phase 3 trial evaluating the role of Finasteride in increasing compliance with Active surveillance, in men with a new diagnosis of low and intermediate risk prostate cancer, when compared with usual care Sheffield Teaching Hospitals NHS Foundation Trust ISRCTN16867955; 2021-004004-17
1004301 A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Lumasiran in Patients with Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels Alnylam NCT05161936; 2021-001519-10
1004313 A Phase  IIb,  Randomised,  Double  Blind,  Placebo  Controlled,  Parallel  Group,  Multicentre Dose Ranging Study of a Subcutaneous Anti-OX40L Monoclonal Antibody (KY1005) in Moderate to Severe Atopic Dermatitis Kymab 2021-000725-28
1004329 A Phase 3, Multi-center, Open-label Extension Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys with Duchenne Muscular Dystrophy (DMD) NS Pharma NCT04768062; 2021-000122-10
1004334 An Open-Label, Phase I Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Preliminary Efficacy Of Ro7443904 In Combination With Glofitamab In Participants With Relapsed/Refractory B-Cell Non-Hodgkin’S Lymphoma Roche 2021-003757-33
1004390 A double-blind, randomized, Phase 1, single ascending dose study to evaluate the safety, tolerability and pharmacokinetic profile of intranasal BPL-003 (5-Methoxy-N,N-dimethyltryptamine benzoate) in healthy subjects Beckley Psytech NCT05347849; 2021-006225-22
1004421 A 2-year randomized, 3-arm, double-blind, non-inferiority study comparing the efficacy and safety of ofatumumab and siponimod versus fingolimod in pediatric patients with multiple sclerosis followed by an open-label extension Novartis NCT04926818; 2020-002700-39
1004424 A Single-Dose Study To Assess The Pharmacokinetics, Tolerability, And Food Effect Of Ptc923 In Healthy Japanese And Non-Japanese Subjects PTC Therapeutics 2021-005897-25
1004506 A Phase 2a, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Prophylactic Efficacy, Safety and Tolerability of INNA-051 in Healthy Adult Participants Challenged with Influenza A/Perth/16/2009 (H3N2) Virus ENA Respiratory NCT05255822; 2021-005701-27
1004587 A Phase II, Multicenter, Randomized, Double Masked, Active Comparatorcontrolled Study To Investigate Theefficacy, Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Ro7200220 In Combination With Ranibizumb Administered Intravitreally In Patients With Diabetic Macular Edema Roche NCT05151744; 2021-004390-31
1004619 A Phase II, Multicenter, Randomized, Double Masked, Active Comparatorcontrolled Study To Investigate The Efficacy, Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Ro7200220 Administered Intravitreally In Patients With Diabetic Macular Edema Roche NCT05151731; 2021-003756-16
1004698 A pragmatic, multi-centre, cluster-randomised trial of an integrated care pathway with a nested, Phase III, open label, adaptive platform randomised drug trial in individuals with Long COVID University College London ISRCTN10665760; 2021-006598-47

Clinical trials given a REC favourable opinion in February 2022

IRAS ID Full study title Sponsor organisation Registration number Further information
226746 A study to establish and modulate the relationship between the microbiome-microglia axis in ALS: an observational study with a subsequent randomised, double-blind, placebo-controlled, faecal microbiota transplant intervention
(BIOMAX-ALS)
University College London 2017-004841-26
262072 A Single Centre, Prospective, Single Arm Open Label Case Series of the TRICENTO, a Transcatheter Tricuspid Valved Stent Graft for  Reduction of Tricuspid Regurgitation and Improved Patient Reported Outcomes in Patients with Carcinoid Heart Disease Queen Mary University of London NCT05064514
268597 Personalised assessment and intervention packages for children with conduct problems in Child Mental Health Services: A randomised controlled trial Tavistock & Portman NHS Foundation Trust ISRCTN15678369
270767 ACcomplisH: A Phase 2, multicenter, double-blind, randomized, placebo-controlled, dose escalation trial evaluating safety, efficacy, and pharmacokinetics of subcutaneous doses of TransCon CNP administered once weekly for 52 weeks in prepubertal children with achondroplasia followed by an Open-Label Extension Period Ascendis Pharma 2019-002754-22
271218 Randomised Double-Blind Placebo-Controlled Phase 3 Trial Of Triumeq In Amyotrophic Lateral Sclerosis King's College London and South London and Maudsley NHS Foundation Trust ISRCTN88446415; 2020-005069-15
280257 A randomised controlled trial to assess the clinical-, technical- and cost-effectiveness of a cloud-based, ARtificially Intelligent image fusion system in comparison to standard treatment to guide endovascular Aortic aneurysm repair (ARIA) King’s College London ISRCTN13832085
280567 STABILITY 2: ACL Reconstruction +/- Lateral Tenodesis with Patellar vs. Quad Tendon University Hospital Coventry & Warwickshire NCT03935750
286722 The use of PET-MRI scan in radiotherapy planning of patients with head and neck cancer: A single centre pilot study Sheffield Teaching Hospitals NHS Foundation Trust NCT06032663
286908 PNEUMACRIT (Preterm Neonate / neonatal Embedded Universal Microelectronic wearable Acquisition for
Cardio Respiratory Intensive Therapy)
NHS Greater Glasgow & Clyde
288415 Pharmacokinetic study of a novel lipid formulation of cannabidiol compared to a standard formulation King’s College London ISRCTN18067579; NCT05032807; 2020-004551-33
289043 Prospective, Randomized Trial Comparing En Bloc with Piecemeal Resection of Neoplasia in Barrett’s Oesophagus University Hospital Hamburg-Eppendorf NCT03427346
291873 Shear Load In-shoe Plantar Sensing/sTRain analysEs And Mapping in diabetic foot ulcers: SLIPSTREAM Leeds Teaching Hospitals NHS Trust NCT05687643
292091 Use of a novel SUBCUTaneous preparation of furosemide to facilitate early supported discharge of patients with Heart Failure: a multicentre, phase II, randomised, parallel group, active comparator controlled trial NHS Greater Glasgow & Clyde 2020-004833-19
293938 Robotic versus Laparoscopic Colon - a Randomized Trial: An international randomised phase II trial comparing robotic-assisted right hemicolectomy versus laparoscopic-assisted hemicolectomy for resection of adenocarcinoma of the caecum, ascending or proximal transverse colon Australasian Gastro-Intestinal Trials Group (AGITG) ACTRN12620001378910
295131 To assess the postoperative changes in fibrinolysis and the utility of tranexamic acid in patients with inherited bleeding disorders Guy's & St Thomas' NHS Foundation Trust Withdrawn before any participants recruited
295564 Invest-CTO: Effectiveness and Safety of a Planned Investment Procedure in High-Risk CTO PCI Haukeland University Hospital NCT04774913
295616 Safety and Performance of FibroFix Cartilage P Implant and Drill Set for Articular Cartilage Repair within the Knee Joint Orthox ISRCTN13615940; NCT05560490
295973 A randomised double-blind, placebo-controlled, trial of rhythmic 10Hz median nerve stimulation for the suppression of the urge-to-tic and reduction of tics in individuals with Tourette syndrome and chronic tic disorder Nottingham University Hospitals NHS Trust NCT05269953
296205 A Sensorimotor Prosthesis of the Upper Limb University Hospitals Coventry & Warwickshire NHS Trust NCT05220552
296584 A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus AstraZeneca 2020-004529-22
296640 PROSpECT-PRIOR-2-CHEMO: A pilot RCT efficacy, mechanistic & process evaluation of a novel dental intervention PRIOR (Proactive Intensive Oral Review & Treatment) in patients scheduled for chemotherapy for myeloma-ASCT, breast or colorectal cancer to mitigate febrile episodes and oral mucositis (OM) University of Leeds Currently registering
296694 POSE-D: Providing Online guided Self-help for Eating disorders in adults with type 2 Diabetes: a pilot study University of Leeds ISRCTN12377526
298619 STOP-OHSS (Shaping and Trialling Outpatient Protocols for Ovarian HyperStimulation Syndrome): A randomised controlled trial to assess the clinical and cost-effectiveness of active management of Ovarian HyperStimulation Syndrome Sheffield Teaching Hospitals NHS Foundation Trust ISRCTN71978064
298679 Feasibility of slow continuous ultrafiltration for deresuscitation in critically ill patients Belfast Health and Social Care Trust NCT05431491 Found through search but HRA not notified
299011 Erector Spinae Plane blocks for the Early Analgesia of Rib fractures in trauma: a multicentre pilot randomised controlled trial with feasibility and embedded qualitative assessment Nottingham University Hospitals NHS Trust ISRCTN49307616
300047 Early diAgnosis Real-Time Healthcare System for CANcer Trial (EARTH SCAN) University College London NCT05064124
300440 Evaluation of circulating endothelial inflammatory biomarkers in response to GLP-1 agonist Semaglutide in acute pulmonary embolisms Imperial College London
300541 Double blind comparison of optimised Deep Brain Stimulation for severe Tourette syndrome (Op-TICS) University College London ISRCTN17008820
300550 Impact of Semaglutide in Amyloid Positivity University of Oxford ISRCTN71283871; 2021-003328-34
300605 Non-Invasive Brainstem Modulation for the Treatment of Non-Motor Symptoms in Parkinson’s Disease: A Randomized Controlled Trial (RCT) and an Open Label Extension (OLE) Study Scion NeuroStim NCT04797611
300650 Improving in-patient experiences of autistic adults by identifying and increasing knowledge about sensory reactivity differences University of Reading Sponsor no longer considers this a clinical trial
301042 Evaluation of the feasibility of a RCT of Empowered Conversations: a training to enhance relationships and communication between family carers and people living with dementia University of Manchester ISRCTN15261686
301118 Inhibition of Bradykinin in SARS-CoV-2 infection with Icatibant (ICASARS) Belfast Health and Social Care Trust NCT05407597; 2021-005851-35
301120 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined with Abiraterone Acetate and Prednisone (AA-P) versus Placebo Combined with AA-P as First-Line Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer Jiangsu Hengrui Pharmaceuticals NCT04691804; 2020-006063-28
301163 An IPA exploration of parents’ experiences of their child receiving a diagnosis of autism using a reframed approach NHS Greater Glasgow & Clyde
301384 A Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously in Patients With Advanced Cutaneous Melanoma or Intravenously in Patients With Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]1 Therapy - ARTISTRY-6 Alkermes NCT04830124; 2021-001557-31
301757 A prospective, multi center, international, open label study of the use of Magseed Pro® markers and Sentimag® Gen3 system to localise breast lesions and suspicious/biopsy-proven positive lymph nodes in breast cancer patients Endomagnetics NCT05142787
302654 Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS-MI): a multi-centre, randomized, placebo-controlled trial NHS Greater Glasgow & Clyde NCT05020704; 2021-006086-38
302657 Actuate 1902: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK - 3β) Inhibitor, as a Single Agent or with Irinotecan, Temozolomide/Irinotecan or Cyclophosphamide/Topotecan in Pediatric Patients with Refractory Malignancies Actuate Therapeutics NCT04239092; 2021-003552-17
303373 The Bedside Evaluation of Sensitive Troponin 2 Study Manchester University NHS Foundation Trust ISRCTN48377837
303611 A Trial investigating the Accuracy of Continuous Glucose Monitor systems (“Supersapiens” Abbott Libre Sense and Dexcom G6) During Exercise in People with Normal Glucose Tolerance (SuperComEx) Imperial College London and Imperial College Healthcare NHS Trust NCT06034574 Found through search but HRA not notified
304283 A Randomised, Double-Blind, Placebo-Controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adult and Adolescent Patients With Moderate-To-Severe Atopic Dermatitis That Are Not Adequately Controlled With Cyclosporine or For Whom Cyclosporine is Not Medically Advisable Almirall 2021-002967-23
304466 Improving the accuracy of chronic kidney disease monitoring using postal finger prick iohexol measured GFR Northern Care Alliance NHS Foundation Trust ISRCTN14717076
304570 Real World Study of the Tendyne™ Mitral Valve System to Treat Mitral Regurgitation (RESOLVE-MR) (Tendyne™ PMCF Study) Abbott NCT04818502
304738 Evaluation of Joint Academy Digital Treatment Programme Intervention for Osteoarthritis Patients in the North of Scotland NHS Highland
304800 Phase 1/2 FIH Study Of Regn5458 (Anti-Bcma X Anti-Cd3 Bispecific Antibody) In Patients With Relapsed Or Refractory Multiple Myeloma Regeneron NCT03761108; 2018-003188-78
304857 intEgrating Smoking Cessation treAtment into usual online Psychological care for people with common mEntal illness: an Online randomised feasibility and pilot study (ESCAPE-O) University of Bath ISRCTN10612149
305026 A Pilot of a Co-Produced Intervention to Increase Hope and Connection for People with Eating Disorders Sussex Partnership NHS Foundation Trust Withdrawn before any participants recruited
305058 A prospective investigation of the concordance of smartphone-based self monitoring, imaging, and blood-based biomarkers with clinical disability in patients with multiple sclerosis within the TONiC program Roche ISRCTN11088592
305381 A Phase 1b Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in Relapsed or Refractory B cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Janssen-Cilag International NCT04876092; 2021-000191-12
305425 A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of QR-421a in Subjects with Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene with Advanced Vision Loss (Sirius) ProQR Therapeutics NCT05158296; 2021-002729-74
305462 The Cognitive Daisy (COG-D) in care homes to support person-centred care: A feasibility CRT University of Lincoln ISRCTN15208844
305508 Fractional Flow Reserve or 3D-Quantitative-Coronary-Angiography Based Vessel-FFR guided revascularization European Cardiovascular Research Institute (ECRI) NCT04931771
305542 A Pragmatic Proof of Concept Study to Evaluate the Effect of Dupilumab on Mannitol Challenge in Severe Asthma with Type 2 Inflammation University of Dundee ISRCTN70810039; 2021-005593-25
305557 Effectiveness and cost effectiveness of an automated text message intervention for weight management in postpartum women with overweight or obesity: the Supporting MumS Randomised Controlled Trial Queen's University Belfast ISRCTN16299220
305610 Should we ligate haemodialysis fistulas in patients after they have been transplanted successfully: the COBALT feasibility study (Cardiorespiratory Optimisation By AVF Ligation after Transplantation) Cambridge University Hospitals NHS Foundation Trust & University of Cambridge ISRCTN49033491
305622 A Randomized, Double Blind, Multicenter, Multinational, Placebo Controlled, Parallel Group, Single Dose, Adaptive Efficacy And Safety Study Of Glenzocimab Used As An Add-On Therapy On Top Of Standard Of Care In The 4.5 Hours Following An Acute Ischemic Stroke Acticor Biotech NCT05070260; 2021-002148-56
305714 A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) Mitsubishi Tanabe Pharma Development America (MTDA) NCT04402489; 2021-001831-17
305840 PATHWAY-RCT: Preventing Admission To Hospital with Attr cardiomyopathy using Remote Cardiac Telemonitoring Richmond Research Institute NCT05098665 Found through search but HRA not notified
305911 A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-2) Immunic Therapeutics NCT05201638; 2021-000029-28
306045 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial: Multiple Independent Sub-studies of Setmelanotide in Patients with POMC/PCSK1, LEPR, NCOA1 (SRC1), or SH2B1 Gene Variants in the Melanocortin-4 Receptor Pathway Rhythm Pharmaceuticals NCT05093634; 2021-002873-24
306188 Rollover Study; Multicentre, Phase III, Open-label Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years with Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed Study PVO-1A-301 or PVO-1A-202/PVO-1A-204 and May Benefit from Palovarotene Therapy Ipsen NCT05027802; 2021-002244-70
306383 A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple Myeloma Janssen-Cilag International NCT05050097; 2020-004502-55
306439 Phase 1 Study Evaluating the Safety and Immunogenicity of COVI-VAC as a Booster Dose in Adults Previously Vaccinated Against COVID-19. (21-012) Codagenix NCT05233826; 2021-005909-27
306514 Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy Gilead NCT05089734; 2021-003578-30
306652 Investigating the application of Narrative Exposure Therapy (NET) to reduce Symptoms of Traumatic Stress in Cancer Patients not in active treatment: a naturalistic single case study series University of Nottingham NCT05272553
306675 Feasibility of implementation of a novel risk calculator informed by natural language processing of electronic health records in the Clinical Records Interactive Search (CRIS) system to enhance routine detection, early intervention and targeted prevention in people at high risk for severe mental illness (SMI) Sussex Partnership NHS Foundation Trust Sponsor no longer considers this a clinical trial
306711 Pilot clinical study to evaluate efficacy of a professionally delivered fluoride varnish on erosive tooth wear in an In-Situ model Colgate-Palmolive NCT06136754
306761 Pharyngeal Electrical stimulation for Acute Stroke dysphagia Trial (PhEAST) University of Nottingham ISRCTN98886991
306799 Multimodal Augmented Reality for Operative Guidance in Oncoplastic Breast Surgery (MAROG - OBS) Imperial College Healthcare NHS Trust
306837 A phase 1-2 multicenter study (2 stages) to evaluate the safety and efficacy of intravenous GNT0006, adeno-associated viral vector carrying the FKRP gene, in patients with FKRP-related limb-girdle muscular dystrophy (LGMD R9, formerly LGMD2I) Atamyo Therapeutics NCT05224505; 2021-004276-33
306846 An open label trial of BI 765063 in combination with BI 754091 (ezabenlimab) alone or with BI 836880, chemotherapy, or cetuximab, in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) or hepatocellular carcinoma (HCC) Boehringer Ingelheim NCT05249426; 2021-003473-59
306964 Exploring Pleural Effusion Research Tools and Drainage Study North Bristol NHS Trust
307764 A feasibility, multicentre randomised control trial assessing the treatment options for patient with major low anterior resection syndrome to establish a Pathway Of Low Anterior Resection syndrome relief after Surgery Cardiff & Vale University Health Board ISRCTN10442425; NCT05319054
307766 Glasses in Classes Pathfinders University of Bradford Sponsor no longer considers this a clinical trial
307879 Determination of feasibility of reversible conduction block generated using StimWave Peripheral nerve stimulator in treatment of focal spasticity and the stimulation parameters for the same. Walton Centre NHS Foundation Trust
308088 A Clinical Evaluation of the DiamondTemp™ System TempeRAture Controlled Ablation for the Treatment of Ventricular Tachycardia. Medtronic NCT03334630 Found through search but HRA not notified
308690 Community-based transcranial direct current stimulation treatment for bipolar depression University of East London NCT05436613 Found through search but HRA not notified
308893 Clinical Assessment of Essential Remote Monitoring Functions in Pacemakers MicroPort CRM NCT05165095
309011 Multicentric, randomized, comparative clinical study on the evaluation of the efficacy and safety of Neovis® Total Multi versus Systane® Balance on the treatment of ocular dryness associated with meibomian gland dysfunction Eurofins NCT05191771
309115 Alternative CErvical Screening (ACES) Over 65's University of Manchester ISRCTN39388293
309287 Trialling an optimised social groups intervention in services to enhance social connectedness and mental Health in vulnerable young people: A feasibility study University of Sussex ISRCTN12505807
309305 Treating Post-Operative Thirst with Flavoured Ice Lollies or Water - a comparative study to improve post-operative discomfort Gloucestershire Hospitals NHS Foundation Trust NCT06014216
310020 A feasibility study to assess the design of a multi-centre randomised controlled trial of the clinical and cost-effectiveness of a caregiving intervention for people with chronic musculoskeletal pain University of East Anglia ISRCTN78169443
310124 Prospective Pilot/Feasibility study on the diagnostic applicability of a Computer-aided detection device (CADU system) for detection of neoplasia in Barrett’s Oesophagus and the use of bio-impedance in risk-stratification Leeds Teaching Hospitals NHS Trust
310265 A randomised controlled feasibility trial protocol comparing face-to-face and video delivery of a specialist preoperative clinic for older people North Bristol NHS Trust ISRCTN95833238
310422 Increasing physical activity levels using e-bikes to enhance breast cancer survival: A randomised pilot study University of Bristol ISRCTN39112034
1003734 A Phase III study of JR-141 in Mucopolysaccharidosis type II (Hunter Syndrome) patients. JCR Pharmaceuticals NCT04573023; 2020-003200-14
1003737 An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy MSD NCT04586231; 2020-002075-35
1003843 A pilot Study of the Use of 129Xe and 1H MRI to measure the Modulation of Eosinophil-Related inflammation by mepolizumab In COPD (SUMMER) Sheffield Teaching Hospitals NHS Foundation Trust NCT05138250; 2021-002901-84
1003910 An Open Label Randomised Trial to Assess the Efficacy of Post-Operative Ferric Maltol Vs Standard Care for Anaemia Following Colorectal Cancer Surgery The Royal Wolverhampton NHS Trust ISRCTN12290106; 2021-006004-32
1003989 Open-label Uncontrolled Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod in Children From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis argenx NCT04833894; 2020-005841-18
1003996 A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma Inhibrx NCT04950075; 2021-002635-35
1004081 A Phase 1b/2, multicenter, single arm study of RBN-2397 in combination with pembrolizumab in patients with Squamous Cell Carcinoma of the Lung (SCCL) Ribon Therapeutics NCT05127590; 2021-003829-30
1004117 A Phase 1b Randomized, Double-Blind, PlaceboControlled, Multiple-Ascending Dose Study to Evaluate  the Safety, Pharmacokinetics, and Pharmacodynamics of ACE-1334 Plus Standard of Care in Participants with Systemic Sclerosis Acceleron Pharma NCT04948554; 2021-001004-15
1004135 A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) Alexion NCT05019521; 2021-001198-22
1004142 A 52-week, open-label, single arm study to investigate the efficacy and safety of mepolizumab SC in participants aged 6 to 17 years with hypereosinophilic syndrome GlaxoSmithKline NCT04965636; 2021-000933-15
1004150 A 2-stage, Adaptive, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate Dose and Treatment Effect of Pentosan Polysulfate Sodium Compared with Placebo in Participants with Knee Osteoarthritis Pain Paradigm NCT04809376; 2021-004030-11
1004155 A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) ADC Therapeutics NCT04970901; 2021-001071-16
1004165 A randomised open-label phase III trial of REduced Frequency pembrolizumab immuNothErapy for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm frequency-response optimisation design Imperial College London ISRCTN70247820; NCT05085028; 2021-004908-18
1004166 A Randomised Placebo-Controlled Trial of Antenatal Corticosteroids for Planned Birth in Twins: STOPPIT-3 University of Edinburgh ISRCTN12345678; NCT12345678; 2021-002876-38
1004177 A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apremilast in Children From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis (PEAPOD) Amgen NCT04804553; 2019-002788-88
1004199 A Phase 3b/4, Double-masked, Randomized, International, Parallel-assignment, Multicenter Trial in Patients with Thyroid Eye Disease to Evaluate the Safety and Tolerability of Different Dosing Durations of Teprotumumab Horizon Therapeutics NCT05002998; 2020-005999-36
1004202 A randomized, open-label, parallel-group, 18-month Phase 3 study to evaluate the effect of venglustat compared with usual standard of care on left ventricular mass index in participants with Fabry disease and left ventricular hypertrophy Sanofi-Aventis NCT05280548; 2021-002320-20
1004226 A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SBT-272 Administered via Subcutaneous Injection in Healthy Subjects Stealth BioTherapeutics ISRCTN12414966; 2021-004584-27
1004307 A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy argenx NCT05225675 ; 2021-003302-50
1004315 A Phase I study for formulation selection and subsequent optimization of two different oral formulations of Nintedanib in healthy male subjects (open-label, randomised, single-dose study in three parts) Boehringer Ingelheim NCT05262751; 2021-003152-16
1004337 A multicentre, open-label, non-randomized, phase 1a/1b study of NG 641, a tumour-selective and transgene-expressing adenoviral vector, in combination with nivolumab in patients with metastatic or advanced epithelial tumours (NEBULA) Akamis Bio NCT05043714; 2021-005570-26
1004344 A Phase II/III, multicentre, 8-week run-in phase followed by a 12- week, prospective, parallel-group, double-blind, randomized withdrawal, placebo-controlled study, with a 52 week open label extension, to evaluate the efficacy and safety of daily 1.5 to 3.5 mg basimglurant in patients with pain associated with trigeminal neuralgia with suboptimal response to their current anti-pain therapy Noema Pharma NCT05217628; 2021-001866-39
1004368 An Open-Label, Randomised, Phase 4 Study of Continuing Sodium Zirconium Cyclosilicate (SZC) after Discharge in Participants with Chronic Kidney Disease treated for Hyperkalaemia AstraZeneca NCT05347693; 2021-003527-14
1004426 A controlled, open-label post-authorisation efficacy and safety study in imlifidase desensitised kidney transplant patients with positive crossmatch against a deceased donor prior to imlifidase treatment, including non-comparative registry and concurrent reference cohorts Hansa Biopharma NCT05369975; 2021-002640-70
1004469 Adjuvant encorafenib & binimetinib vs. placebo in fully resected stage IIB/C BRAF V600E/K mutated melanoma: a randomized triple-blind phase III study in collaboration with the EORTC Melanoma Group Pierre Fabre NCT05270044; 2021-004310-19
1004519 A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of Subcutaneously and Intravenously Administered ALXN1910 in Healthy Adult Participants Alexion NCT05307978; 2021-005847-58
1004521 Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab and Are Judged by the Investigator to Clinically Benefit From Continued Treatment AstraZeneca NCT05303532; 2021-003031-29
1004536 A Phase 1, Randomized, Double-blind, Placebo-controlled, Single- and Multiple-dose Escalation Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Oral VX‑708 in Healthy Subjects Vertex 2021-005559-35
1004538 A FIRST-IN-HUMAN, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF INS-3001 IN HEALTHY SUBJECTS AND PATIENTS WITH MODERATE AORTIC VALVE STENOSIS Inositec ISRCTN76722400 ; 2021-001969-20
1004561 A Phase 1, Open-Label, Dose Finding Study of CC-95251 Alone and in Combination with Antineoplastic Agents in Subjects with Acute Myeloid Leukemia and Myelodysplastic Syndromes Celgene NCT05168202; 2021-002799-38
1004578 A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Single Ascending and Multiple Dose Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALN-XDH in Healthy Adult Subjects and Adult Patients with Gout Alnylam NCT05256810; 2021-005773-68
1004612 Efficacy and safety of COMP360 psilocybin therapy in anorexia nervosa: a proof-of-concept study COMPASS Pathfinder NCT05481736; 2021-006233-19
1004636 Open-Label Study to Investigate Pharmacokinetics, Mass Balance and Metabolite Profiles of NRD135S.E1 in Healthy Adult Male Volunteers Novaremed ISRCTN51059297; 2021-006502-76
1004656 A randomised phase 2 study of ASTX727 versus best supportive care in MDS/MPN Overlap Syndromes University of Birmingham ISRCTN30808508; 2021-004585-35
1004766 A Phase 3 Open-label Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 2 Years and Older Vertex NCT05153317; 2020-002239-31
1004941 A Phase 2/3, Randomized, Observer-blind, Active-controlled, Multicenter Study to Evaluate the Immunogenicity and Safety of mRNA-1273.529 (B.1.1.529, Omicron Variant) in Comparison with mRNA-1273 (Prototype) Booster Vaccine ModernaTX ISRCTN99890480; 2022-000063-51
1004956 A multi-part, adaptive Phase 1, first time in human, single centre study in human volunteer subjects to assess safety, tolerability, Pharmacokinetics (PK) of single ascending (SAD) and multiple ascending doses (MAD) of MTX652, including optional study parts to assess effect of food, formulation, potential drug-drug interaction liability and a comparison of elderly versus non-elderly participants Mission Therapeutics 2021-006764-24
309578/312087 Evaluation of a nutritionally complete, plant-based, high energy, high protein, enteral tube feed in adults Nutricia NCT05411848

Clinical trials given a REC favourable opinion in March 2022

IRAS ID Full study title Sponsor organisation Registration number Further information
239047 Does relative hypoglycaemia &/or sleep disturbance contribute to the lethargy observed in Addison’s disease Leeds Teaching Hospitals NHS Trust NCT05515055
253369 SMART composite (Self-bonding Material for Atraumatic Restorative Treatment) restoration of children’s primary molar teeth after minimal caries removal: Class IIa device in a single site, single arm study University College London ISRCTN14233369
257601 InGReS: Intra-treatment Image Guided Adaptive Radiotherapy Dose-escalation Study - a Phase 1 multicentre feasibility study Guy's & St Thomas' NHS Foundation Trust NCT05393297 Found through search but HRA not notified
269464 The feasibility of a multi-phasic exercise-based intervention utilising the Health Action Process Approach and wearable technology in women before and after surgery for breast cancer Royal Derby Hospital NCT05901142
274384 Reducing the impact of diabetic foot ulcers (REDUCE): A effectiveness and cost-effectiveness Randomised Controlled Trial University Hospitals Derby & Burton NHS Foundation Trust ISRCTN15570706
274984 Analysis of endotracheal tube biofilm (including type of bacteria, biofilm architecture and structural components) in patients who have been intubated for 5 or more days University College London
276445 Performance and Function of the Trident® II 3D printed Acetabular Component South Tees Hospitals NHS Foundation Trust ISRCTN57876689
278006 Safe and Effective Above Cuff Tracheostomy Vocalisation (SEA CtV) Manchester University NHS Foundation Trust NCT04647786
279630 The effects of an innovative Glycomacropeptide based protein supplement purified to lower the phenylalanine content for the treatment of paediatric patients with Phenylketonuria Cambrooke Currently registering
279799 A study of medical device Dermastat® to assess its suitability as a new autonomic neuropathy testing device, in the diabetes clinical setting Manchester University NHS Foundation Trust
280185 Management of impacted maxillary central incisors: a multicentre randomised clinical trial King’s College London ISRCTN12709966
281209 The Growth Hormone Deficiency Reversal Trial: Effect on final height of discontinuation vs continuation of growth hormone treatment in pubertal children with isolated growth hormone deficiency – A non-inferiority randomised controlled trial University College London ISRCTN12552768; 2020-001006-39
282624 Risk reduction intervention for raised blood pressure (REVERSE): A feasibility study exploring the use of blood pressure self-monitoring University of Central Lancashire ISRCTN13649483
287604 Evaluation of Pre-hospital use of a Valsalva Assist Devise (VAD) in the Emergency treatment of supraventricular tachycardia (SVT). A stepped-wedge cluster randomised controlled  trial  [EVADE SVT] South Western Ambulance Service ISRCTN16145266
288108 Eye gaze technology for endoscopic inspection of the gastrointestinal tract Imperial College London
288219 In vivo molecular mapping of adult primary brain tumour activity using novel magnetic resonance imaging (MRI): a pilot study Erasmus MC NCT05140785
290012 Measuring biomarkers using aptamers Imperial College London Currently registering
291671 Diagnostic accuracy of WEARable TECHnology single-lead ECG in detecting cardiac arrhythmias: WEAR-TECH ECG Oxford University Hospitals NHS Foundation Trust NCT05298553
292085 Post Delivery intervention in women with previous gestational diabetes mellitus for glycaemia and cardiovascular health Imperial College London NCT06022601
292170 Evaluating the test performance of Aspergillus antigen detection using a lateral flow device (LFD) on broncho-alveolar lavage (BAL) fluid for the diagnosis of invasive pulmonary Aspergillosis in Paediatrics: A Pilot Study St George’s University Hospitals NHS Foundation Trust NCT05569824 Found through search but HRA not notified
292873 A double-blinded feasibility study of intraoperative electron radiotherapy in patients with locally advanced or locally recurrent rectal cancer University Hospital Southampton NHS Foundation Trust ISRCTN48105173
293244 Computed Tomography Coronary Angiography (CTCA) prior to Chronic Total Occlusion (CTO) Percutaneous Coronary Intervention (PCI) - a feasibility study Sandwell and West Birmingham NHS Trust NCT05364827
294362 Production of expanded autologous regulatory T cells to treat patients with aplastic anaemia: A phase I study King’s College London NCT05386264; 2021-000082-33
294369 The RAPID 2 study. Reducing Anxiety in Pregnancy: Intervention Development phase 2. A feasibility study of a midwife facilitated supportive intervention Nottingham University Hospitals NHS Trust ISRCTN12834758
294387 BASELINE Trial: Balloon Expandable versus Self Expanding Transcatheter Valve for Degenerated Bioprosthesis Leeds Teaching Hospitals NHS Trust NCT04843072
294429 Echocardiographic assessment of cardiotoxicity in adult cancer patients receiving trastuzumab and other HER2-targeted cancer therapies: comparison of manual and with automated analyses Ultromics Trial did not open in the UK
295171 Feasibility study: An investigation of frailty and glycaemic control in older adults with Type 1 diabetes mellitus University Hospitals Sussex NHS Foundation Trust ISRCTN30513341
295297 Olanzapine for young PEople with aNorexia nervosa: An open-label feasibility study to test recruitment, treatment acceptance, adherence, safety, and outcome measures assessment and patients' experience to prepare for a definitive randomised placebo-controlled trial King’s College London ISRCTN80075010; 2021-004598-30
295968 Virtual 3D modelling for improved surgical planning of robotic-assisted partial nephrectomy King’s College London NCT05109182
297102 Using a diffuse reflectance spectroscopy probe in-vivo to identify tumour and non-tumour tissue in the gastrointestinal tract to aid margin assessment Imperial College London NCT05830292
298364 A Pilot Study to Investigate the Use of Remote Thermovisual Monitoring in Patients with a Previous Diabetic Foot Ulcer, during the COVID-19 pandemic Bluedrop Medical NCT05039645
298827 ACHIEVE - An adaptive trial of the efficacy and effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded allogeneic γδ T-lymphocytes (TCB008) for patients with refractory or relapsed acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPNs) TC BioPharm NCT05358808; 2021-000744-22
299052 IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients with Pulmonary Arterial Hypertension (PAH) Aerovate Therapeutics 2021-001910-13
299128 BARI-STEP: A double-blinded, randomised, placebo-controlled trial of semaglutide 2.4 mg in patients with poor weight-loss following bariatric surgery University College London NCT05073835; 2021-004568-83
299687 Is intensive upper limb rehabilitation effective in chronic stroke patients? A randomised controlled trial (INTENSE) University College London & University College Hospital Hospitals NHS Foundation Trust NCT05527262
300753 Multi-centre, randomised controlled trial of Vinehealth® digital health cancer solution for cancer patients commencing chemotherapy University of Surrey ISRCTN44293246
301154 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment AbbVie NCT04972968; 2021-000648-23
301186 Validation and implementation of a Digital Assessment Routing Tool (DART) as an alternative to physiotherapy-led triage: A Pilot Randomised Crossover Non-Inferiority Trial QMUL and Bart's Health NHS Trust NCT04904029
301301 MEsenteric Excision and Kono-S Anastomosis Trial (MEErKAT) Sheffield Teaching Hospitals NHS Foundation Trust ISRCTN16900055
301656 Prospective evaluation of clinical and radiographic outcomes after Anterior Cervical interbody fusion surgery using a TRYPTIK® Ti-Life cage Spineart ISRCTN63972735
301682 Psychosis Immune Mechanism Stratified Medicine Trial: The PIMS Trial University of Bristol ISRCTN23256704
301730 Feasibility Randomised Controlled Trial of Remotely Delivered EMDR versus Face to Face EMDR for Post Traumatic Stress Disorder (PTSD) in Military Veterans Cardiff University ISRCTN13912752
301795 A Combined Home-Based Exercise and Nutritional Approach to Improve Frailty Status in Kidney Transplant Recipients: A Randomised Controlled Feasibility Study University of Birmingham Currently registering
301966 Efficacy of a Streamlined Heart failure Optimisation pRoTocol for patients with severely impaired left ventricular systolic function, a randomised controlled trial (SHORT trial) Queen Elizabeth Hospital NHS Foundation Trust NCT05021419
302276 Early detection of bladder cancer in Yorkshire: Feasibility assessments for implementing a targeted study in populations with high disease specific mortality risk University of Sheffield ISRCTN34273159
302295 EAGLET: EEG vs CFM (aEEG) to improve the diagnosis of neonataL seizures and Epilepsy – a randomised Trial Cambridge University Hospitals NHS Foundation Trust NCT05079971
302587 Providing Emotional Support Around the Point of Multiple Sclerosis Diagnosis: PrEliMS 2 University of Nottingham NCT05225012
302666 PROMIZE: A Phase I/II Trial to Assess the Safety, Tolerability and Preliminary Anti-tumour Activity of Oral Combination antibiotic therapy to modulate the microbiome in combination with enzalutamide in metastatic castration resistant prostate cancer (mCRPC) The Institute of Cancer Research 2021-004559-18
303042 Fasting or non-fasting before cardiac catheterization Blackpool Teaching Hospitals NHS Foundation Trust NCT05133206
303093 DISCOVER "Getting the Life You Want" Workshop Programme for Care Experienced young people aged 16-19: A feasibility and acceptability pilot study South London and Maudsley NHS Foundation Trust NCT05220436
303180 A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease Agios NCT05031780; 2021-001674-34
303421 DOLFIN - Developmental Outcomes of Long Term Feed Supplementation in Neonates Newcastle Upon Tyne Hospitals NHS Foundation Trust ISRCTN62323236
303525 A randomised, multi-centre, double-blind, placebo-controlled, single ascending dose, multiple dose study to assess safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of intravenous infusion doses of ONO-4685 in patients with plaque psoriasis (21-502) ONO Pharma NCT05332704; 2021-002151-10
304193 A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment Amgen NCT05060016; 2021-002566-40
304235 A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN Sotorasib) in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation Amgen NCT04185883; 2020-004721-23
304351 Phase 1/2 Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT7480 in Patients With Nectin-4 Associated Advanced Malignancies BicycleTx NCT05163041; 2021-004468-80
304633 Hydrotherapy for health in boys and adolescents with Duchenne muscular dystrophy Lancashire Teaching Hospitals NHS Foundation Trust Currently registering
304723 Dynamic susceptibility contrast MRI Perfusion assessment of brain metastases: baseline characteristics and the study of pattern of perfusion change in suspected radionecrosis post-stereotactic radiosurgery (STARBEAM-X) Newcastle Upon Tyne Hospitals NHS Foundation Trust ISRCTN62305334
304762 Promoting Restoration of Function of Co-ordinated Bladder Storage and Voiding following SCI by Combination of tSCS and Bladder & Pelvic Floor Muscle Training Royal National Orthopaedic Hospital NHS Trust NCT05504200
304807 A Phase I, Multi-Center, Open-Label Study To Assess The Safety, Pharmacokinetics, And Preliminary Efficacy Of An Orally Available Small Molecule, Cc-99282, Alone And In Combination With Anti-Lymphoma Agents In Subjects With Relapsed Or Refractory Non-Hodgkin Lymphomas (R/R Nhl) Celgene NCT03930953; 2018-003235-29
304825 PROSAIC-DS Study (PROState AI in Cancer - Decision Support)

Evaluation of the Deontics AI platform for personalised, evidence-based treatment planning in multidisciplinary cancer care: Increasing compliance with national standards of care and streamlining MDTs in prostate cancer.
Guy's & St Thomas' NHS Foundation Trust NCT05355727 Found through search but HRA not notified
304974 Clinical Impact of the iBox as an early Intervention tooL: A prospective randomized controlled trial to assess the use of a software predicting allograft survival in the follow-up of kidney transplanted patients Predict4Health NCT05112315
305174 Improving care for patients living with persistent non-cancer pain and taking opioid medicines long-term: A multicentre cluster randomised controlled trial of proactive clinical review led by practice pharmacists in primary care. The PROMPPT Trial. Keele University ISRCTN45616481
305313 Implementation of a medicines management plan (MMP) to reduce medication related harm (MRH) in older people post hospital discharge: a randomised controlled trial University of Sussex ISRCTN16864276
305446 A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy and of Magrolimab in Combination with Nab-Paclitaxel or Paclitaxel versus Nab-Paclitaxel or Paclitaxel in Previously Untreated Patients with Metastatic Triple-Negative Breast Cancer Gilead NCT04958785; 2021-001074-27
305449 Virtual Evaluations of joint health using wearable Sensors in Persons with haemophiliA (VESPA) East Kent Hospitals University NHS Trust NCT06046235 Found through search but HRA not notified
305731 Prehabilitation of swallowing difficulties in people with head and neck cancer: A pilot cluster randomised trial and process evaluation University College London ISRCTN12377415
305899 A Randomized, Double-blind Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of ASC-201 Plus Trifluridine/Tipiracil Compared With Trifluridine/Tipiracil in  Patients With Advanced Gastric Cancer in a Third Line Treatment Setting After an Initial Dose Escalation Phase Ascelia Pharma 2021-003799-15
305929 Upper Limb Telerehabilitation Using Brain-Controlled Functional Electrical Stimulation Sheffield Teaching Hospitals NHS Foundation Trust ISRCTN42991002
305973 The CALM trial: the clinical and cost-effectiveness of a guided self-help cognitive  behavioural therapy intervention to reduce dental anxiety in children Sheffield Teaching Hospitals NHS Foundation Trust ISRCTN27579420
306043 A Phase 1/2 Study of the Oral RET Inhibitor LOXO-292 in Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors Loxo Oncology NCT03899792; 2019-000212-28
306610 Does Virtual Reality Reduce Pain and Anxiety During Outpatient Hysteroscopy? A Randomised Controlled Trial Imperial College Healthcare NHS Trust NCT05307887
306642 The Nurtured Heart Parenting Intervention for Children’s Behavioural Problems: A Single Case Design University of Lincoln NCT06195579
306747 Diabetes Risk Assessment and Medical Referral or Signposting (DRAMeRS) NHS Education for Scotland ISRCTN16798215
307085 Complex ePrescribing-based Antimicrobial Stewardship intervention for Hospitals (ePAMS+) Feasibility Trial University of Edinburgh ISRCTN13429325
307122 Exploring the potential of ‘JIA Toolbox’ in improving the independence and functional ability of Children and Young People (CYP) with Juvenile Idiopathic Arthritis (JIA) Sheffield Children's NHS Foundation Trust NCT05563194
307220 A Phase 1B, Adaptive, Multi-Center, Randomized, Double Blind, Placebo-Controlled, Parallel Design Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Ro7486967 In Participants With Early Idiopathic Parkinson’S Disease Roche ISRCTN85338453; NCT05924243; 2021-002345-15
307429 Immersive Virtual Reality for Dysphagia Treatment after Stroke Sheffield Hallam University Currently registering
307434 Orthodontic Patient Experience of Intraoral Scanners Versus Alginate Impressions in the UK: a Single-Centre Randomised Controlled Crossover Trial University Hospitals Derby & Burton NHS Foundation Trust NCT05194956
307439 Tailored abdominal massage treatment for constipation in adults with learning disabilities – A Feasibility study and Pilot trial Glasgow Caledonian University NCT05490654
307457 A Phase 2, Long-Term Extension (LTE) Study with Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus Who Have Completed the M19-130 Phase 2 Randomized Controlled Trial (RCT) AbbVie NCT04451772; 2020-001690-72
307635 Increasing physical activity levels using e-bikes to enhance prostate cancer survival: A randomised pilot study University of Bristol ISRCTN42852156
307732 Evaluation of the 24/7 EEG™ SubQ System for Ultra Long-Term Recording of Patients with Temporal Lobe Epilepsy UNEEG Medical NCT04526418
307933 IdeNtification of SPecific EleCTrophenotypes in Atrial Fibrillation – INSPECT-AF Imperial College London NCT05366530
308038 Stroke Biomarker Evaluation for Large Vessel Occlusion (StroBE-LVO) Northumbria Healthcare NHS Foundation Trust ISRCTN60633358
308255 A Phase 2a, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of AT-1501 in Patients with IgA Nephropathy Eledon Pharma NCT05125068; 2021-004795-34
308546 PASSION-HF (Patient Self-care uSing eHealth In chrONic Heart Failure) CAPITALISATION University of Suffolk
308605 The feasibility of Frame Running as an exercise option for people with MS with impaired balance and mobility Queen Margaret University NCT05234879
308680 To evaluate the acceptability (including gastrointestinal tolerance and compliance) of an adult tube-feed formula with ingredients derived from food Nestle Health Science NCT06102122 Found through search but HRA not notified
308691 A Phase 2, randomised, double-blind, placebo-controlled, dose escalation study to investigate the effects of IRL201805 in participants with moderately to severely active rheumatoid arthritis Revolo Biotherapeutics 2021-005771-39
309178 Randomised controlled trial of the Community Navigator programme to reduce loneliness and depression for adults with treatment resistant depression in secondary mental health services Camden & Islington NHS Foundation Trust ISRCTN13205972
309506 Validation of In Vitro Diagnostic Assays at External Clinical Laboratories The Binding Site
309738 An interventional, prospective IVD device study for the testing of DNA extracted from tumor tissue biopsy samples from patients with Colorectal Cancer (CRC) who have previously tested positive for KRAS G12C mutation into the Amgen Phase III clinical trial (Protocol No 20190172) to demonstrate clinical performance of the therascreen® KRAS RGQ PCR Kit. QIAGEN NCT05347745; 2021-004008-16
309915 Transcranial Direct Current Stimulation In Major Depressive Disorder: A Double-Blind, Placebo-Controlled, Randomized, Superiority Trial Flow Neuroscience
309937 Effect of immuno-nutrition on systemic inflammation in people receiving haemodialysis: a pilot study University of Nottingham NCT05700851
310212 A study to evaluate the performance of a Lab-on-Chip LAMP device for rapid SARS-CoV-2 diagnosis University of Bath ISRCTN58218165
310426 An open label, pilot study to determine the effect of weekly intra-cavernosal injections of Invicorp on male Erectile Dysfunction (ED) post radical prostatectomy RestoriT ISRCTN77251669; 2021-005456-11
310662 Investigating the viability and acceptability of an Interactive Virtual Reality (IVR) System on physiotherapy rehabilitation in paediatric Duchenne Muscular Dystrophy (DMD) patients Sheffield Children's NHS Foundation Trust NCT06274983
310691 A pragmatic randomised control trial comparing the efficacy of the “Free from Pain Exercise Book” versus “The Back Book” in decreasing back pain in adults over 60 years of age Talita Cumi NCT05359107
311052 SAPIEN SBRI 19 Impact of a remote lifestyle change program on length of stay and complications in patients undergoing elective knee and hip arthroplasty Sherwood Forest Hospitals NHS Foundation Trust ISRCTN12049495
311106 Randomised trial of intra-articular injection of lidocaine versus placebo in Inflammatory arthritis Guy's & St Thomas' NHS Foundation Trust NCT05302232 Found through search but HRA not notified
311663 Investigating Value-Based Procurement and patient reported outcomes from adults with lymphoedema using a 12-week home-based programme of LymphAssistTM (intermittent pneumatic compression) Swansea Bay University Health Board NCT05456568
311906 Exploring Right vEntricular function applicability in a Prediction mOdel to identify pReterm infanTs with early BronchoPulmonary Dysplasia (REPORT – BPD Study): a mixed methods observational cohort feasibility study University Hospital Plymouth NHS Trust NCT05235399
312115 Sample collection for evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel Abbott NCT05354115
312287 A Single-centre, Single-Blinded, Randomized, Crossover Study to Assess the Nicotine Pharmacokinetic Profile Following Use of two Variants of Logic Compact in Adult Healthy Electronic Cigarette Users Japan Tobacco ISRCTN97168882
1003562 A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects with Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open–Label Vedolizumab Intravenous Therapy Takeda NCT04779307; 2020-004300-34
1003594 A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects with Moderately to Severely Active Crohn’s Disease Who Achieved Clinical Response Following Open–Label Vedolizumab Intravenous Therapy Takeda NCT04779320; 2020-004301-31
1003686 Phase 1/2 Study of Bempegaldesleukin in Combination with Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Malignancies (PIVOT IO 020) Bristol-Myers Squibb NCT04730349; 2020-000854-85
1003822 AttackMS - Natalizumab for the treatment of people with inflammatory demyelination suggestive of multiple sclerosis, or definite multiple sclerosis, at first presentation Queen Mary University of London NCT05418010; 2021-002255-11
1003956 A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With An Open-Label Extention Period To Evaluate The Efficacy And Safety Of Rozanolixizumab In Adult Participants With Myelin Oligodendrocyte Glycoprotein (Mog) Antibody-Associated Disease (Mog-Ad) UCB NCT05063162; 2021-000352-19
1004038 A randomized phase II trial evaluating Ibrutinib plus CD20 Ab and Ibrutinib-Venetoclax plus CD20 Ab in patients with untreated mantle cell lymphoma Lymphoma Academic Research Organisation NCT04802590; 2020-004910-37
1004207 A randomized, double-blind, placebo-controlled, 12 month Phase 3 study to evaluate the effect of venglustat on neuropathic and abdominal pain in male and female adults with Fabry disease who are treatment-naïve or untreated for at least 6 months Sanofi-Aventis NCT05206773; 2021-002350-90
1004225 A randomized, double-blind, parallel group, placebo-controlled, multicenter Phase 3 trial to evaluate the efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in patients with active lupus nephritis (SIRIUS-LN) Novartis NCT05126277; 2020-005830-14
1004234 A randomized, double-blind, phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for metastatic HER2+ breast cancer (HER2CLIMB-05) Seagen NCT05132582 ; 2021-002491-39
1004264 A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Crohn's Disease Eli Lilly and Company NCT04232553; 2019-002687-27
1004294 A Phase Ia/B Open-Label Study To Evaluate Safety, Pharmacokinetics, And Preliminary Clinical Activity Of Ro7276389 Alone And In Combination With Cobimetinib In Participants With Braf-V600 Mutation-Positive Advanced Solid Tumor Or Braf-V600 Mutation-Positive Melanoma With Central Nervous System Metastases Roche ISRCTN13713551; 2021-003426-77
1004303 Multimodal METformin and FINGER lifestyle intervention to prevent cognitive impairment and disability in older adults at risk for dementia: a phase IIb multi-national randomised, controlled trial Imperial College London NCT05109169; 2021-005213-14
1004317 Obeticholic acid for the Amelioration of Cognitive Symptoms trial - 3 Newcastle Upon Tyne Hospitals NHS Foundation Trust ISRCTN98936300; 2020-004958-30
1004318 An Open Label, Randomised, Phase 2 Study To Evaluate The Safety And Efficacy Of Mtl-Cebpa Administered In Combination With Sorafenib Or Sorafenib Alone, In Tki Naïve Participants With Previously Treated Advanced Hepatocellular Carcinoma (Hcc) And Hepatitis B Or Hepatitis C Virus (Outreach2) MiNA Alpha NCT04710641; 2021-005431-23
1004379 Phase 1 study of base edited CAR7 T cells to treat T cell malignancies (TvT CAR7) Great Ormond Street Hospital for Children NHS Trust ISRCTN15323014; 2021-004312-25
1004384 A Double-Blinded, Placebo-controlled, Multi-center Randomized,  Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801  in Subjects with Type 2 Diabetes Mellitus with Inadequate  Glycemic Control on Diet Control Alone or on Diet Control and Glucose-lowering Agents as Monotherapy Oramed NCT04754334; 2021-004226-30
1004402 A Phase 3 Multi-Center, One-Year, Open-Label study of Setmelanotide in Pediatric Patients Aged 2 to <6 years of age with Rare Genetic Causes of Obesity Rhythm Pharmaceuticals NCT04966741; 2021-004167-27
1004415 A Phase 2b Multicenter, Randomized, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis Janssen-Cilag International ISRCTN76915275; NCT05223868; 2021-003700-41
1004430 A phase III randomized, controlled, open-label, multicenter, global study of capmatinib in combination with osimertinib versus platinum - pemetrexed based doublet chemotherapy in patients with locally advanced or metastatic NSCLC harboring EGFR activating mutations who have progressed on prior EGFR-TKI therapy and whose tumors are T790M mutation negative and harbor MET amplification (GEOMETRY-E) Novartis NCT04816214; 2020-003677-21
1004431 A 24 week, randomised, assessor blinded, active-controlled, parallel group, phase 3, 2 arm trial to compare the efficacy and safety of delgocitinib cream 20 mg/g twice-daily with alitretinoin capsules once-daily in adult participants with severe chronic hand eczema LEO Pharma ISRCTN44123892; 2021-003543-16
1004437 A Phase 1b Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-110 in Combination with Abiraterone in Patients with Metastatic Prostate Cancer Arvinas NCT05177042; 2021-003046-21
1004443 A Double-Blind, Placebo-Controlled, Dose Escalation Study to Assess the Efficacy, Safety and Pharmacokinetics of Voclosporin in Adolescents with Lupus Nephritis Aurinia NCT05288855; 2020-005807-37
1004452 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Subjects With Pyruvate Kinase Deficiency Who Are Regularly Transfused, Followed by a 5-Year Open-label Extension Period Agios NCT05175105; 2021-003265-36
1004459 An Open-label Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Inebilizumab in Pediatric Subjects with Neuromyelitis Optica Spectrum Disorder Horizon Therapeutics NCT05549258; 2021-003528-33
1004471 ATR inhibitor elimusertib (BAY 1895344) in combination with cisplatin or irinotecan in participants with advanced solid tumors Bayer 2021-004397-57
1004477 A Phase 2 Study of Galicaftor/Navocaftor/ABBV-119 Combination Therapy in Subjects with Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation AbbVie ISRCTN48897533; NCT04853368; 2020-005805-25
1004490 A phase 1/1b/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP null solid tumors Amgen NCT05094336; 2021-004764-10
1004491 A randomised feasibility study evaluating the effect of perioperative intravenous lIdocaine on colorectal cancer outcome after surgery Imperial College London ISRCTN29594895; NCT05250791; 2021-006185-20
1004498 Effects of N-Acetyl-L-Leucine on Niemann-Pick disease type C (NPC): A Phase III, randomized, placebo-controlled, double-blind, crossover study IntraBio NCT05163288; 2021-005356-10
1004503 A Phase I, Double-Blind, Placebo-Controlled, Ascending Single Intravenous Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Participants and Non-Cystic Fibrosis Bronchiectasis Patients colonized with Pseudomonas aeruginosa administered INFEX702 Infex Therapeutics ISRCTN17978477; 2021-005018-32
1004505 A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022) MSD NCT05239728 ; 2021-003436-92
1004512 A Randomized, Double-blind, Placebo-controlled Single Ascending Dose and Open-label Multi-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-APP in Adult Patients with Early-onset Alzheimer’s Disease (EOAD) IQVIA NCT05231785; 2021-003198-74
1004525 A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) who are receiving an angiotensin II receptor blocker (ARB) Dimerix ISRCTN72772236; NCT05183646; 2021-004174-64
1004548 A Phase III, double-blind, placebo-controlled, Randomized, Multicenter, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy (PACIFIC-9) AstraZeneca NCT05221840; 2021-004346-37
1004579 A Randomised Active-controlled Study to Compare Efficacy and Safety of Inhaled Isoflurane Delivered by the AnaConDa-S (Anaesthetic Conserving Device) to Intravenous Midazolam for Sedation in Mechanically Ventilated Paediatric Patients 3 to 17 (Less than 18) Years Old Sedana Medical ISRCTN12741394; NCT04684238; 2020-000578-31
1004590 An open-label extension trial to evaluate the long-term safety of apraglutide in short bowel syndrome VectivBio NCT05018286; 2020-005513-41
1004620 A 12-week parallel group, randomized, placebo-controlled, doubleblinded, multi-center study to evaluate efficacy and safety of 2 concentrations of SAF312 eye drops (5 mg/ml and 15 mg/ml) used twice-daily in the treatment of post-operative corneal induced chronic pain (CICP) following Photorefractive Keratectomy (PRK) or Laser assisted in Situ Keratomileusis (LASIK) surgeries Novartis NCT04630158; 2021-005857-97
1004650 A double-blind, randomized, placebo-controlled, phase 1 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of single- and multiple-ascending doses of intravenously administered anti-LIGHT monoclonal antibody CBS001 in healthy volunteers Capella Bioscience NCT05323110; 2021-006484-21
1004685 A Randomized, Double-Blind, Phase 3 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination with Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants with Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) MSD NCT05226598; 2021-004564-94
1004688 An Open-Label, 3-Arm, Multicenter, Randomized Phase 3 Study To Evaluate The Efficacy And Safety Of Elranatamab (Pf-06863135) Monotherapy And Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone In Participants With Relapsed/Refractory Multiple Myeloma Who Have Received At Least 1 Prior Line Of Therapy Including Lenalidomide And A Proteasome Inhibitor Pfizer NCT05020236; 2021-000044-22
1004711 A Phase 1 Single- and Multiple-Ascending Dose Study of the Safety and Pharmacokinetics of a Gastro-Retentive Formulation of 5-Hydroxytryptophan (5-HTP) and Low-Dose Carbidopa (EVX-101) in Healthy Subjects Taking Escitalopram Evecxia Therapeutics ISRCTN42835524; 2021-006715-28
1004748 A TWINSS extension trial to evaluate the safety and tolerability of CFZ533 (iscalimab) at two dose levels administered subcutaneously in patients with Sjögren’s Syndrome Novartis NCT04541589; 2020-001942-20
1004767 Interventional, open-label, positron emission tomography (PET) study with [11C]-Lu AF88370 investigating blood-brain barrier penetration of Lu AF88370 in healthy men Lundbeck NCT05320302; 2021-005082-40
1004785 A Parallel-group (2-Arm), Randomized, Double-blind, 12 week Trial to Evaluate the Efficacy and Safety of MC2 25 Cream and MC2-25 Vehicle in Subjects with Chronic Kidney Disease-associated Pruritus (CKD aP) MC2 Therapeutics ISRCTN74524864; 2021-006971-40
1004827 A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Hypercholesterolemia MSD NCT05261126; 2021-005221-24
1004837 An exploratory, single-centre, open-label, crossover study in healthy volunteers using scintigraphy to evaluate the absorption of buspirone\nhydrochloride from timed-release tablets Cingulate 2021-006396-42
1004843 A Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of SAR443820 in adult participants with amyotrophic lateral sclerosis, followed by an open-label extension Sanofi-Aventis NCT05237284; 2021-004156-42
1004853 A Phase 1, Multiple Part, Open Label Trial to Evaluate the Pharmacokinetic Profile of KVD824 Following Administration of KVD824 Gastro Retentive Formulation Prototypes in Healthy Volunteers KalVista Pharmaceuticals ISRCTN14984568; 2021-006855-33
1004864 Four-part, Randomized, Double-blind (Parts 1, 2A, 3 and 4), Multi-center, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK3965193 Monotherapy in Healthy Participants and in Participants Living with Chronic Hepatitis B Infection; and GSK3965193 in Combination with Bepirovirsen in Participants Living with Chronic Hepatitis B Infection GlaxoSmithKline NCT05330455; 2021-005117-13
1005009 A Phase 1 Single Dose Study to Evaluate the Pharmacokinetics of CORT113176 Softgel Capsules in Healthy Subjects Corcept Therapeutics ISRCTN52169163; 2022-000181-18
1005025 A Phase I Study to Investigate the Absolute Bioavailability, Absorption, Metabolism, Distribution and Excretion of [14C]AZD5363 (Capivasertib) in Healthy Male Subjects AstraZeneca ISRCTN15620353; 2022-000277-59
1005072 A Phase 1, Randomized, Open-Label Trial Assessing Pharmacokinetics and Safety of Low-Dose CAM2038 q4w in Healthy Volunteers Under Naltrexone Blockade Camurus 2022-000393-26
302989/314513 The EXTEND trial: Fixed-extended-duration antibiotics (28 days) compared to standard care antibiotic durations in adult patients with complicated intra-abdominal infection and their impact on treatment failure - a phase III multicentre, open label, two-arm, parallel group, pragmatic, randomised controlled trial with internal pilot University of Leeds ISRCTN72819021; NCT05148702
308830/299977 The impact of REStrictive versUs Liberal Transfusion strategy on cardiac injury and death in patients undergoing surgery for Hip Fracture (RESULT-Hip) University of Edinburgh ISRCTN28818784

Clinical trials given a REC favourable opinion in April 2022

IRAS ID Full study title Sponsor organisation Registration number Further information
263064 CHARRT (Carcinoid Heart Disease and Radiotargeted Peptide Receptor Therapy): Pilot randomised trial to assess progression of carcinoid heart disease in patients treated with Lutathera therapy compared to best supportive care King’s College Hospital NHS Foundation Trust NCT04039516; 2019-001632-61
269958 Aspirin versus placebo in twin pregnancies for preeclampsia prevention: A multicenter, randomised, double-blind, placebo-controlled trial (ASPRE-T) Fundación para la Formación e Investigación Sanitarias de la Región de Murcia 2019-003341-15
271346 A Phase III, Multicenter, Open-Label, Uncontrolled Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aqp4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (Nmosd) Roche NCT05199688; 2019-004092-39
274003 Muscle MRI in patients with McArdle Disease (Glycogen storage disease type V) University College London & University College Hospital Hospitals NHS Foundation Trust NCT03844022
280900 A single-centre, randomised, cross-over design feasibility study to assess the effectiveness of an app-based, assisted behavioural change techniques to improve HbA1c levels and support  diabetes self-management in young adults and adolescents Manchester University NHS Foundation Trust NCT05217953
288979 Assessing metabolic profiling strategies for nutritional management in diabetic patients with Non-Alcoholic Fatty Liver Disease Imperial College London
290193 To examine the effectiveness of physical activity, Quality of Life and Hospital Anxiety and Depression outcomes in Cardiovascular patients using an internet-based Cardiac Rehabilitation application compared with a conventional Cardiac Rehabilitation programme or a combination of both University Of Chester NCT05326529
292223 PROMETHEUS: Prospective tRial of Machine lEarning To Help fEtal Ultrasound Scanning King’s College London ISRCTN65824874
294633 Feasibility And Acceptability Of A Uk Based Remote Brain Health Clinic For Patients With Mild Cognitive Impairment (Mci) South London and Maudsley NHS Foundation Trust
295426 A Phase IIb, Randomised-Controlled, Two-Centre Clinical Trial (Exalt) On The Efficacy Of A Home-Based Exercise And Motivational Programme In Patients Before And After Liver Transplantation University of Birmingham ISRCTN13476586
295523 Reducing Microvascular Dysfunction In Patients With Angina, Ischaemia And Unobstructed Coronary Arteries – A Pilot Study (Remedy-Pilot) Imperial College London NCT05492110
295721 TrueBlue Clinical Study - Investigating the use of a mobile phone app TrueBlue for monitoring Depression and Anxiety BlueSkeye AI Recruitment not yet started
296997 SUCCESS (SelUtion, safety, effiCaCy, hEalth economicS and promS) PTA Study M.A. Med Alliance NCT04776434
297292 Diastolic function assessment with cardiac magnetic resonance imaging and echocardiography: a scan-rescan study Imperial College Healthcare NHS Trust NCT05438030
298524 An observational longitudinal cohort study to investigate Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer’s disease (CONGA) University Hospital Southampton NHS Foundation Trust NCT05579236
298717 A Feasibilty Study and Process Evaluation of an Integrated Support Programme for Adults Following a Diagnosis of Type 1 Diabetes- the Living with and ADapting to DiabetEs PRogramme (LADDER) King’s College London ISRCTN17358613
299927 A Prospective, Open Label, Cross-Over, Multi-Center Pilot Study To Evaluate The Safety, Feasibility And Usability Of The Intelligent Dialysis Assistant (Ida) In Subjects With Chronic Kidney Disease Stage V Treated With Peritoneal Dialysis IiberDi Ltd. NCT04808011
299961 PREhabilitation for Patients Awaiting liveR transplantation: development and feasibility testing of a remote multicomponent prEhabilitation intervention: PREPARE Belfast Health and Social Care Trust NCT06036225 Found through search but HRA not notified
300846 A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Patients with Dravet Syndrome (ARGUS Trial) Epygenix Therapeutics NCT04462770; 2021-003425-30
301143 A pragmatic trial of an Artificial intelligence DRiven appOInTment maNagEment SyStem London South Bank University ISRCTN16329124
301473 Post market surveillance study to confirm the ongoing safety and performance of Silver II Non-woven dressing in chronic and acute wounds Advanced Medical Solutions NCT05045430
301533 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participants with Fibrodysplasia Ossificans Progressiva Incyte NCT05090891; 2021-002286-17
301799 Piloting a web-based personalised nutrition app (eNutriCardio) with patients offered cardiac rehabilitation University of Reading NCT05449769
302075 Non-inferiority of angiography-derived physiology guidance versus usual care in an All-comers PCI population treated with unrestricted use of the Healing-Targeted Supreme (HT SupremeTM) drug-eluting stent and P2Y12 inhibitor monotherapy after 1-month of dual-antiplatelet therapy: the PIONEER IV trial National University of Ireland NCT04923191
302147 Sensing OxygeN saturations usinG aBdominal NIRS with an Investigational Realtime Device (Songbird) – CTOM UK (Carag Tissue oxygenation Monitor System/CTOM) CARAG NCT05278247
303347 Effects of selective left subclavian ansae stimulation on human cardiac electrophysiological properties - a potential percutaneous target for neuromodulation in Atrial Fibrillation Barts Health NHS Trust NCT05133414
303650 Phase Ib, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Assess The Safety Of Ro7486967 In Patients With Chronic Obstructive Pulmonary
Disease
Roche 2021-000558-25
303674 A feasibility study examining the use of Mechanical Insufflation Exsufflation to promote extubation success in adult intensive care University Hospitals Bristol and Weston NHS Foundation Trust ISRCTN24603037
305038 Hypobaric Oxygen during cardiopulmonary bypass to reduce gaseous Micro-Emboli during cardiac surgery: a randomised controlled trial University Hospitals Bristol and Weston NHS Foundation Trust ISRCTN87042095
305321 Is Method of Levels (MOL) Therapy An Acceptable And Feasible Psychological Intervention For People Using Acute Mental Health Inpatient Services? A Case Series University of Manchester NCT05377294
305393 A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined with Nivolumab versus Placebo with Nivolumab in Patients with Unresectable or Metastatic Melanoma Not Previously Treated with PD-1 or PD-L1 Inhibitors HUYABIO International 2019-002521-30
305395 High Dose Steroids in Children with Stroke and Unilateral Focal Arteriopathy: A Multicentre Randomized Controlled Trial PASTA (Paediatric Arteriopathy Steroid Aspirin) trial University Childrens Hopital Inselspital Bern NCT04873583; 2021-005571-39
305780 A randomised controlled trial to evaluate heat therapy in the treatment of peripheral artery disease: clinical benefit and mechanisms of action Coventry University Recruitment not yet started
305839 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment Neurocrine Biosciences NCT04806451; 2020-004381-19
306062 CANcer BEhavioural Nutrition and Exercise FeasibilIty Trial (CanBenefit): Phase II randomised controlled trial among older adults with lung cancer University of Hull NCT05404022
306160 A Randomised Control Trial of Power versus Temperature-controlled radiofrequency irrigated ablation for the treatment of Ventricular Tachycardia (VT) University Hospital Coventry & Warwickshire NCT06028919
306291 Improving sleep and learning in rehabilitation after stroke, part 2 University of Oxford NCT05511285
306347 Is there a dose response effect on bone characteristics in relation to drop jump height? Nottingham Trent University NCT06282705
306485 A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) Alexion NCT05097989; 2021-001426-22
306772 A feasibility study of a Behavioural Intervention for Opioid Reduction (BIOR) for chronic non-cancer pain patients in primary care Liverpool John Moores University ISRCTN30201337
306954 A Proof-of-Concept Study of The Complete Vocal Technique (CVT), a pedagogic technique used for Performers, in Improving the Voice and Vocal Function in Patients with Muscle Tension Dysphonia Nottingham University Hospitals NHS Trust NCT05365126
307103 Improving engagement and recovery in people with early psychosis through Method of Levels therapy delivered by care coordinators: Feasibility cluster randomised controlled trial Greater Manchester Mental Health NHS Foundation Trust ISRCTN14082421
307116 Determining the Effectiveness of a FeNO-guided asthma management intervention in primary care: a pragmatic randomised controlled trial with nested economic and process evaluations University of Oxford ISRCTN16411887
307150 Dietary Approaches to the Management Of type 2 Diabetes (DIAMOND) cluster randomised trial University of Oxford ISRCTN46961767
307437 Personalised Speech and Language Therapy for Children and Young People with Cerebral Palsy using Acoustic and Phonological Analytics Newcastle University Currently registering
307603 A Phase 1 Study of Safety, Pharmacokinetics and Preliminary Activity of TAS1553 in Subjects with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms Astex NCT04637009; 2021-003593-31
307862 Early vasopressors in Sepsis NHS Greater Glasgow & Clyde NCT05179499; 2021-006886-39
308065 A randomised trial comparing ‘self-etch primer’ and ‘conventional etch and primer’ for orthodontic bonding in the hospital clinical setting Western Health and Social Care Trust
308393 A single-centre, open-label study testing the safety and performance of the Glyconics-SX System in assessment of glycated nail keratin, compared with a standardised glycated haemoglobin (HbA1c) assay, in individuals with or without type 2 diabetes Glyconics Limited NCT05198895
308557 Efficacy of Personalised Irradiation with Rhenium-Skin Cancer Therapy (SCT) for the treatment of non-melanoma skin cancer; a phase IV multi-centre, international, open label, single arm study Oncobeta NCT05135052
308656 Pilot study on the use of a Virtual Reality Tour to reduce anxiety in patients referred for PET/CT scans Oxford University Hospitals NHS Foundation Trust ISRCTN50051799
308677 A Phase 1b study in patients with acromegaly or functioning gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to characterize the pharmacokinetics, pharmacodynamics, safety and tolerability of Debio 4126, a 12-week prolonged-release octreotide formulation Debiopharm NCT05364944; 2021-005035-23
308755 Best Endovenous treatment, including STenting, versus best non-endovenous treatment in chronic proximal deep venous disease – the BEST multi-centre randomised controlled trial Imperial College London NCT05622500
308812 A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms Incyte NCT04279847; 2020-003532-25
308883 A Phase 1 Study of TAS0612 in Patients with Locally Advanced or Metastatic Solid Tumors Taiho Oncology NCT04586270; 2020-002304-39
309110 Post Marketing Study to Evaluate Millipede 088 Effectiveness for Clot Retrieval in Acute Ischemic Stroke Perfuze
309300 Technical feasibility of neo-commissural alignment in Trans-Catheter Aortic Valve Implantation (TAVI):  an exploratory study describing procedural outcomes and effect on coronary blood flow measured by cardiac computed tomography (CT) University Hospitals Sussex NHS Foundation Trust ISRCTN16090439
309510 Star-Life: A Post-Market Registry On Miniject iSTAR Medical NCT05269680
310090 A randomised, double blind sham controlled clinical trial to evaluate the efficacy of vestibular nerve stimulation (VeNS), together with a lifestyle modification program, compared to a sham control with a lifestyle modification program, as a means of improving glycaemic control in adults with type 2 diabetes mellitus Neurovalens NCT04595968
310192 Post-market Clinical Follow-up (PMCF) Study of the Infinity-Lock™ Button System for Acromioclavicular Joint Stabilisation Xiros NCT05397210
310423 Cognitive Remediation in Bipolar (CRiB2): a randomised trial assessing efficacy and mechanisms of cognitive remediation therapy compared to treatment as usual King's College London and South London and Maudsley NHS Foundation Trust ISRCTN10362331
310455 Efficacy of Energy Therapy in the management of chronic pain in children and adolescents King’s College Hospital NHS Foundation Trust NCT05394272
310742 Electrocorticography as a Neurophysiological Marker for Intraoperative Monitoring of Brain Retraction University College Hospital Hospitals NHS Foundation Trust
311121 Smart Watch Insights for the Prevention of Exacerbations and Enhance Rehabilitation  - Movement Study (SWIPER-MOVES) Imperial College London NCT06011356 Found through search but HRA not notified
311214 Multimorbidity in Older Adults with Depression Study (MODS)
(Working Title: Managing Multiple Health Conditions in Older Adults)
Tees Esk and Wear Valleys NHS Foundation Trust ISRCTN44184899
311569 Project Verio Vue Enhancements Regulatory Clinical Evaluation – Professional Comparison to Validated Method - Arterial Study LifeScan NCT06121856
311664 Extracorporeal Shockwave Therapy for Diabetic Foot Ulcers: A Pilot 3-Arm Randomised Control Trial and Qualitative Study (SOLEFUL) Hull University Teaching Hospitals NHS Trust NCT05380544
311795 Upper Limb Rehabilitation using immersive Virtual Reality for people with Multiple Sclerosis; a feasibility trial Glasgow Caledonian University NCT05320237
311902 Development of an Artificial Intelligence System for the Automated Diagnosis of Otitis Media with Effusion in Children Cardiff Metropolitan University ISRCTN17082829
312494 CompreHensive GeriAtRician led MEdication Review (CHARMER) - Work Package 3 Feasibility Trial University of Leicester ISRCTN11899506
313100 IDEntifying pAtients with suspicion of infection in the ED who have Low disease severity using Midregional Proadrenomedullin (MR-proADM) - Pivotal study B·R·A·H·M·S NCT05108883
1004052 A Phase 1, Blinded, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of BIIB132 Administered Intrathecally to Adults With Spinocerebellar Ataxia 3 Biogen ISRCTN94357046; 2021-002223-37
1004248 A Phase III, Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Gantenerumab In Participants At Risk For Or At The Earliest Stages Of Alzheimer’S Disease Roche ISRCTN54460428; 2021-001184-25
1004279 A Phase 2 Trial of MRTX849 Monotherapy and in Combination withPembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer withKRAS G12C Mutation Mirati Therapeutics ISRCTN13464104; NCT04613596; 2020-003101-58
1004338 A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102) Amgen NCT05111626; 2021-003477-61
1004360 A Randomized, Double-Blinded, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability, Effect of Food and Absolute Bioavailability of BMS-986238 in Healthy Participants Bristol-Myers Squibb ISRCTN17572332; 2020-004521-23
1004364 Phase 1 Study of the PKMYT1 Inhibitor RP-6306 in Combination With Gemcitabine for the Treatment of Advanced Solid Tumors (MAGNETIC Study) Repare Therapeutics NCT05147272; 2021-006541-34
1004373 A Randomized, Double-Blind, Placebo-Controlled Study of ATH434 in Multiple System Atrophy Alterity Therapeutics NCT05109091; 2021-003231-29
1004380 Longwing: An Open-Label Extension Study for Patients with Dravet Syndrome who Previously Participated in Studies of STK-001 Stoke Therapeutics NCT04740476; 2021-005626-14
1004406 ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC) Insmed ISRCTN15403905; NCT04677569; 2020-003079-16
1004432 An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy Regeneron NCT02290951; 2015-004491-30
1004480 A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients with Mild-to-Moderate Hypertension Alnylam NCT04936035; 2021-001248-82
1004485 Mifepristone Outpatient Labour Induction Chelsea and Westminster Hospital NHS Foundation Trust NCT05177510; 2021-004860-93
1004546 A Double-Blind, Randomised, Placebo Controlled, Two Period Cross-Over Study To Evaluate The Efficacy And Safety Of Orvepitant In Chronic Cough In Patients With Idiopathic Pulmonary Fibrosis NeRRe Therapeutics ISRCTN12372820; NCT05185089; 2021-006278-22
1004562 Randomized, Open Label, Phase 3 Study to Evaluate the Efficacy and Safety of Lerodalcibep (LIB003) compared to Inclisiran in  Patients With Cardiovascular Disease, or at High Risk for Cardiovascular Disease, on Stable Lipid-Lowering Therapy Requiring Additional Low-Density Lipoprotein Cholesterol Reduction (LIBerate-VI) LIB Therapeutics NCT05004675; 2021-002871-20
1004577 A Multicenter, Randomized, Open-label, Parallel Phase 1 Comparability Study of Anifrolumab Administered using Accessorized Pre-Filled Syringe (APFS) or Autoinjector (AI) in Healthy Volunteers AstraZeneca ISRCTN93026854; 2021-004896-14
1004593 A Phase 2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients with Refractory Myelodysplastic Syndrome Karyopharm Therapeutics 2021-003810-38
1004594 IOCYTE AMI-3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Intravenous FDY-5301 in Patients with an Anterior ST-Elevation Myocardial Infarction Faraday Pharmaceuticals NCT04837001; 2021-001924-16
1004596 A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination with Radiotherapy with or without Temozolomide and in Recurrent Glioblastoma as Single Agent Novartis NCT05109728; 2021-003672-14
1004601 A phase 1b/2, multicenter, adaptive, double-blind, randomized, placebo-controlled study to assess the safety, tolerability, immunogenicity, and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer’s disease and in adults with Down syndrome AC Immune NCT05462106; 2021-006195-17
1004634 A First-In-Human Phase 1b, Open-Label Trial to Evaluate Safety and Tolerability of a Novel Somatic Cell Therapy - AmnioPul-02 - in Subjects with Confirmed COVID-19 Amniotics 2020-004171-40
1004639 A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Familial Chylomicronemia Syndrome Arrowhead Pharmaceuticals ISRCTN12904794; 2021-003680-10
1004672 A Phase I/II Open-label, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma AstraZeneca NCT05216835; 2021-003569-36
1004686 Obicetrapib and Cardiovascular Outcomes: A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease (ASCVD) Who are Not Adequately Controlled Despite Maximally Tolerated Lipid-Modifying Therapies NewAmsterdam Pharma NCT05202509; 2021-005092-39
1004699 Phase 1 Study of the PKMYT1 Inhibitor RP-6306 in Combination With FOLFIRI for the Treatment of Advanced Solid Tumors (MINOTAUR Study) Repare Therapeutics NCT05147272; 2021-006582-38
1004740 A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients with Phlebotomy Dependent Polycythemia Vera (PD-PV) Ionis NCT05143957; 2021-003704-40
1004749 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus UCB NCT04294667; 2019-003407-35
1004761 ENHANCE-D: Enhancing Dental Health Advice Newcastle Upon Tyne Hospitals NHS Foundation Trust ISRCTN13158982; 2021-005440-30
1004762 A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV Disease MSD NCT04938830; 2020-005996-11
1004771 A randomised, double-blind, parallel group Phase III study to assess the efficacy and safety of 100 mg SC depemokimab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) – ANCHOR-1 (depemokimAb iN CHrOnic Rhinosinusitis) GlaxoSmithKline NCT05274750; 2021-005037-16
1004808 A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer (KEYVIBE-008) MSD NCT05224141; 2021-005034-42
1004811 A Phase 2, Open-Label, Multi-Center Study of PDS0101 (R-DOTAP [Versamune®] + HPVmix) and Pembrolizumab (KEYTRUDA®) Combination Immunotherapy in Subjects with Recurrent and/or Metastatic Head and Neck Cancer and High-Risk Human Papillomavirus-16 (HPV16) Infection PDS Biotechnology ISRCTN15021247; NCT04260126; 2021-004046-38
1004844 A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination with New Hormonal Agents in Patients with Metastatic Prostate Cancer (PETRANHA) AstraZeneca NCT05367440; 2021-006289-19
1004851 A Phase 1, Randomized, Double-blind, 3-arm, Parallel Design Study in Healthy Subjects to Evaluate Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Bmab 1200 After Single Subcutaneous Injection inComparison with EU-approved Stelara® and US-licensed Stelara® Biocon Biologics ISRCTN11424009; 2021-006630-39
1004852 An open-label study in healthy male subjects to investigate the metabolism  and excretion pathways of GLPG3667 following a single oral dose of [14C]-GLPG3667 and to determine the absolute bioavailability relative to an intravenous [14C]-GLPG3667 microtracer Galapagos NCT05335447; 2021-006730-39
1004906 Phase 3, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Apitegromab (SRK-015) in Patients with Later-Onset Spinal Muscular Atrophy Receiving Background Nusinersen or Risdiplam Therapy Scholar Rock NCT05156320; 2021-005314-34
1004936 Randomized, single-dose, open-label, two-part, two-period, cross-over study to compare the pharmacokinetics, safety and tolerability of the pediatric and adult formulation of branaplam and to investigate the adult formulation in fed and fasted state in healthy participants Novartis ISRCTN77772103; 2021-000298-10
1004948 A Phase 1, Open-Label, Dose finding Study of CC-95251, A Monoclonal Antibody Directed Against SIRPα, Alone and in Combination with Cetuximab or Rituximab in Subjects with Advanced Solid and Hematologic Cancers Celgene NCT03783403; 2020-000240-55
1004972 A Multicentre, Single-arm, Phase 3b Efficacy and Safety Study of Tezepelumab 210 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Participants with Severe Asthma on High-dose Inhaled Corticosteroid plus Long-acting β2 Agonist and Long-term Oral Corticosteroid Therapy (WAYFINDER) AstraZeneca NCT05274815; 2021-005457-85
1004979 A Phase 3 Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ISIS 721744 in Patients with Hereditary Angioedema (HAE) Ionis NCT05139810; 2021-002571-19
1004984 A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1 3 Alterations (FIGHT-209) Incyte NCT05267106; 2021-004740-24
1004992 A first-in-human, randomized, participant and investigator blinded, placebo controlled, single and multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of EDI048 in healthy volunteers Novartis ISRCTN38693215; 2021-006567-19
1005024 A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTE-C93/GOG-3064/ENGOT-en15) MSD NCT05173987; 2021-003185-12
1005049 A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of SAR443765 in healthy adult participants and of a single dose of SAR443765 in participants with mild-to-moderate asthma Sanofi-Aventis NCT05366764; 2021-000356-19
1005082 A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator’s Choice of Chemotherapy in Patients who are not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast02) AstraZeneca NCT05374512; 2021-005223-21
1005096 An open label, multicenter roll-over extension program (REP) to characterize the long-term safety and tolerability of iptacopan (LNP023) in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have completed PNH Phase 2 and Phase 3 studies with iptacopan Novartis NCT04747613  ; 2020-004385-19
1005098 A Phase 1 Clinical Study to Determine the Safety and Immunogenicity of a Novel GMMA Vaccine Against Invasive Non-Typhoid Salmonella University of Oxford ISRCTN51750695; 2020-000510-14
1005125 A 52 week, multi-center, randomized, double-blind placebo-controlled study to assess the clinical efficacy and safety of ligelizumab (QGE031) in decreasing the sensitivity to peanuts in patients with peanut allergy Novartis ISRCTN04984876; NCT04984876; 2020-005339-56
1005171 A Phase 1, open-label trial in healthy participants to evaluate the drug-drug interaction potential of PRAX-562 Praxis 2022-000583-22
1005228 A Phase I, open-label, fixed-sequence, two-period, crossover, drug-drug interaction study to investigate the effect of efavirenz on the pharmacokinetics of ganaplacide and lumefantrine combination in healthy participants Novartis NCT05330273; 2021-000925-29
1005259 A Phase I, Open-Label, Single-Dose, Single-Period Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833 After Oral Administration in Healthy Post-Menopausal Female Subjects AstraZeneca ISRCTN46127225; 2022-000834-40
1005293 A Phase 1, Randomised, Open-Label, Crossover Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of PBI-4050 compared to Sodium Phenylbutyrate in Healthy Subjects Liminal BioSciences NCT05349435; 2022-000804-36

Clinical trials given a REC favourable opinion in May 2022

IRAS ID Full study title Sponsor organisation Registration number Further information
254656 A 2-armed, parallel, randomised controlled trial to assess the effect of different modes of fluoride delivery, on enamel demineralisation, during orthodontic treatment with fixed appliances, in children and adolescents Liverpool University Hospitals NHS Foundation Trust NCT05005689; 2018-004335-76
280123 The effect of Semaglutide compared to metformin in obese women with polycystic ovary syndrome (PCOS): a randomised controlled trial (Semaglutide-PCOS study-SEMMET) Hull University Teaching Hospitals NHS Trust 2021-001361-20
293364 Phase two prospective observational single blind multi-site performance evaluation trial of serum Raman spectroscopy and supervised machine learning classification in FIT-positive bowel screening population Swansea Bay University Health Board
293754 Determining Who Benefits Most from Cognitive Rehabilitation for Attention and Memory in Multiple Sclerosis: A Randomised Controlled Feasibility Trial University of Nottingham NCT05509426
294635 KEEP- A randomised feasibility study of a co-designed physical health education intervention to improve Knowledge, Exercise Efficacy and Participation for newly diagnosed people with Parkinson’s Cambridge University Hospitals NHS Foundation Trust & University of Cambridge NCT05253040
297538 Study of precision and reproducibility of non-invasive glucose testing with the LabClasp Cambridge University Hospitals NHS Foundation Trust & University of Cambridge
297626 OUtcome following Tailored Education and Retraining: Studying Performance and Adherence in ChildrEn and young people with asthma: a Randomised feasibility Study (OUTER-SPACERS) University Hospitals of North Midlands NHS Trust NCT05366309
298095 OKKO Space Academy App: families checking their child's vision at home during amblyopia treatment Moorfields Eye Hospital NHS Foundation Trust NCT05313516 Found through search but HRA not notified
299054 Validation of Innovative Scheimpflug topography derived RGP contact lens designs In Optometry Network (VISION Initiative) Moorfields Eye Hospital NHS Foundation Trust
299552 An open label, single arm, extension trial to examine long-term safety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials.(CONNEX-X) Boehringer Ingelheim NCT05211947; 2020-003745-11
300137 Protection of Cardiac Function with Left Bundle Branch Pacing in Patients with Atrioventricular Block (OptimPacing) The First Affiliated Hospital Nanjin Medical University NCT04624763
300243 Multi-centre Prospective observational cohort study: To assess the performance of single use duodenoscope (aScope) Nottingham University Hospitals NHS Trust NCT05225909
300545 Defatting of donor transplant livers during normothermic perfusion - a randomised clinical trial University of Oxford ISRCTN14957538
301345 Imaging of tumour microvasculature using high resolution contrast enhanced ultrasound (CEUS) together with markers of proliferation/ angiogenesis/ vascular mimicry to characterise response to NACT in triple negative breast cancer Maidstone & Tunbridge Wells NHS Trust
301912 ROTATE
Rotation of the fetal head at full cervical dilatation Randomised controlled trial of manual versus instrumental rotation of the fetal head in malposition at birth
University College London ISRCTN10193017
303325 Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for  Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in (Golden Gate Study) Amgen NCT04994717; 2020-004498-29
303378 DOLCE: Determining the Impact of Optellum’s LCP Artificial Intelligence Solution on Service Utilisation, Health Economics and Patient Outcomes Nottingham University Hospitals NHS Trust NCT05389774
303690 Imperial Prostate 7 -  Prostate Assessment using Comparative Interventions – Fast mri and Image-fusion for Cancer Imperial College London NCT05574647
303703 Randomised investigation to evaluate Phe fluctuation after overnight fasting in PKU patients treated with PKU GOLIKE versus standard amino acid protein substitute APR Applied Pharma Research NCT05487378 Found through search but HRA not notified
303720 A Phase 1/2a, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered Alone and in Combination with Pembrolizumab, in Patients with Advanced Solid Tumors Turnstone Biologics Corp NCT04301011; 2021-001001-79
303731 A Phase 2 Multi-Arm Study of Magrolimab in Patients with Solid Tumors Gilead NCT04827576; 2020-005265-14
305144 Effectiveness and cost-effectiveness of a peer-led walking programme to increase physical activity in inactive older adults: “Walk with Me Study” University of Ulster ISRCTN73367347
305172 Utility of PET-MRI in post-treatment surveillance of paediatric brain tumours: a feasibility study Sheffield Children's NHS Foundation Trust NCT05553899
305912 A randomised phase II study to investigate the effectiveness of ACUpuncture for the relief of Long COVID related fatigue The Royal Marsden NHS Foundation Trust NCT05212688
306620 Cluster Randomised Controlled Trial of a Service to Support the Mental Health and Coping of Parents with Excessively Crying Infants De Montfort University ISRCTN73761296
306658 The effectiveness and acceptability of a guided self-help ACT intervention for individuals with a spinal cord injury (SCI) University of Nottingham
306829 Financial incentives to improve adherence to inhaled asthma medications in children and young people with asthma Imperial College London NCT05322044
306946 SPIROmetry to Manage Asthma in Children (SPIROMAC) University of Aberdeen ISRCTN31849868
306996 Biomarker Driven Antifungal Stewardship (BioDriveAFS) in Acute Leukaemia – a Multi-Centre Randomised Controlled Trial to Assess Clinical and Cost Effectiveness Hull University Teaching Hospitals NHS Trust ISRCTN11633399
307300 Remote monitoring to predict and prevent asthma attacks in preschool children Imperial College London NCT05447832
307759 First in human study of Sirona: A study to determine safety, feasibility and tolerability of an expanding hydrogel tablet, designed to promote weight loss in adults with a body mass index of 30-40 Oxford Medical Products ISRCTN12345678
307827 Analysis of a motivational chairwork intervention for adults diagnosed with Anorexia Nervosa Canterbury Christ Church University Sponsor no longer considers this a clinical trial
307875 A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Transfusion-Dependent β-Thalassemia Vertex 2021-002172-39
307888 PACE-NODES: A phase III randomised trial of 5 fraction prostate SBRT versus 5 fraction prostate and pelvic nodal SBRT The Institute of Cancer Research NCT05613023
307968 Mechanisms driving headache in Idiopathic Intracranial Hypertension, a human physiology study